DrugRepV|Encyclopedia for antivirals

DrugRepV Browse Page

DrugRepV browse page allows user to take a glance of the particular antiviral agent.Fields in the webpage is hylerlinked ot various external repositories like DrugBank, PubChem, Clinicaltrials.gov,and PubMed.User can explore the biological, Clinical, Chemical, and Structural details of every repurposed drug candidate.By clicking on the table header arrows, user can sort entries in ascending or descending order.

Total number of Records for Plaque assay are 738

DrugRepV_ID	Antiviral Name	Drug type	Primary Indication	Secondary Indication	Strain	Pathways	Assay	Activity	Clinical Status	References
DrugRepV_0005	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	Decrease (100 %)	Approved	29033372
DrugRepV_0006	Clomiphene Citrate	Genito Urinary System and Sex Hormones	Female infertility	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	Decrease (100 %)	Approved	29033372
DrugRepV_0007	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	Decrease (60 %)	Approved	29033372
DrugRepV_0008	Alverine Citrate	Alimentary Tract and Metabolism	Spasms of the stomach and intestines	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	Decrease (60 %)	Approved	29033372
DrugRepV_0009	Sertraline Hydrochloride	Nervous System	Depressive disorder \| Post-traumatic stress disorder \| Obsessive-compulsive disorder \| Panic disorder \| Premenstrual dysphoric disorder \| Social anxiety disorder	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	Decrease (50 %)	Approved	29033372
DrugRepV_0010	Tamoxifen	Antineoplastic and Immunomodulating Agents	Breast cancer	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	No significant effect (45 %)	Approved	29033372
DrugRepV_0011	Amiodarone	Cardiovascular agents	Anginal and Arrhythmia	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	No significant effect (45 %)	Approved	29033372
DrugRepV_0012	BHSA	NA	NA	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	No significant effect (45 %)	NA	29033372
DrugRepV_0013	Fluoxetine Hydrochloride	Nervous System	Major depressive disorder \| Bulimia nervosa \| Obsessive-compulsive disorder \| Premenstrual dysphoric disorder \| Panic disorder with or without agoraphobia	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	No significant effect (40 %)	Approved, Vet approved	29033372
DrugRepV_0014	Anthocyanidin	Plant extract	NA	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	No significant effect (20 %)	NA	29033372
DrugRepV_0015	Chlorogenic Acid	NA	Cancer	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	No significant effect (10 %)	Investigational	29033372
DrugRepV_0016	Tetrandrine	NA	Congestive circulatory disorder and inflammatory diseases	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	No significant effect (0 %)	Experimental	29033372
DrugRepV_0017	Mibefradil	Cardiovascular agents	Angina \| High blood pressure	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	No significant effect (0 %)	Investigational, Withdrawn	29033372
DrugRepV_0018	Fluvastatin	Cardiovascular agents	Cardiovascular disease (Coronary heart disease (CHD))	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	Increase (110 %)	Approved	29033372
DrugRepV_0019	Delphinidin Chloride	NA	NA	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	Increase (110 %)	NA	29033372
DrugRepV_0020	Erythromycin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	Increase (120 %)	Approved	29033372
DrugRepV_0046	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus \| Acquired immunodeficiency syndrome	Zika virus	H/PF/2013	NA	Plaque assay	Decrease (50 %)	Approved	28912011
DrugRepV_0048	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus \| Acquired immunodeficiency syndrome	Zika virus	ZIKVNL00013	NA	Plaque assay	Decrease (50 %)	Approved	28912011
DrugRepV_0050	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus \| Acquired immunodeficiency syndrome	Zika virus	H/PF/2013	NA	Plaque assay	No significant effect (0 %)	Approved	28912011
DrugRepV_0051	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus \| Acquired immunodeficiency syndrome	Zika virus	ZIKVNL00013	NA	Plaque assay	No significant effect (0 %)	Approved	28912011
DrugRepV_0054	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus \| Acquired immunodeficiency syndrome	Zika virus	H/PF/2013	NA	Plaque assay	No significant effect (0 %)	Approved	28912011
DrugRepV_0055	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus \| Acquired immunodeficiency syndrome	Zika virus	ZIKVNL00013	NA	Plaque assay	No significant effect (0 %)	Approved	28912011
DrugRepV_0056	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	H/PF/2013	NA	Plaque assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0057	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	ZIKVNL00013	NA	Plaque assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0060	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	H/PF/2013	NA	Plaque assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0061	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	ZIKVNL00013	NA	Plaque assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0064	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	H/PF/2013	NA	Plaque assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0065	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	ZIKVNL00013	NA	Plaque assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0066	Sunitinib	Antineoplastic and Immunomodulating Agents	Renal cell carcinoma \| Gastrointestinal stromal tumor	Zika virus	MR766	NA	Plaque assay	Decrease (50 %)	Approved, Investigational	28240606
DrugRepV_0067	Erlotinib	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MR766	NA	Plaque assay	Decrease (50 %)	Approved	28240606
DrugRepV_0071	Sunitinib	Antineoplastic and Immunomodulating Agents	Renal cell carcinoma \| Gastrointestinal stromal tumor	Chikungunya virus	181/25	NA	Plaque assay	Decrease (50 %)	Approved, Investigational	28240606
DrugRepV_0072	Erlotinib	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	181/25	NA	Plaque assay	Decrease (50 %)	Approved	28240606
DrugRepV_0077	Bromocriptine	Nervous System	Parkinson disease	Zika virus	Puerto Rico strain PRVABC-59	NA	Plaque assay	Decrease (>99 %)	Approved	28185815
DrugRepV_0080	Intron A	Antineoplastic and Immunomodulating Agents	Hairy cell leukemia \| Malignant melanoma \| AIDS-related Kaposi's sarcoma	Zika virus	Puerto Rico strain PRVABC-59	NA	Plaque assay	Decrease (>99 %)	Approved	28185815
DrugRepV_0083	Avonex	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Zika virus	Puerto Rico strain PRVABC-59	NA	Plaque assay	Decrease (>99 %)	Approved	28185815
DrugRepV_0086	Rebif	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Zika virus	Puerto Rico strain PRVABC-59	NA	Plaque assay	Decrease (>99 %)	Approved	28185815
DrugRepV_0089	Betaferon	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Zika virus	Puerto Rico strain PRVABC-59	NA	Plaque assay	Decrease (>90 %)	Approved	28185815
DrugRepV_0092	Imukin	NA	NA	Zika virus	Puerto Rico strain PRVABC-59	NA	Plaque assay	Decrease (>90 %)	Approved, Investigational	28185815
DrugRepV_0274	Nalidixic Acid	Antiinfectives For Systemic Use	Bacterial infections	Influenza virus	A/New Jersey/15/2007		Plaque assay	Decrease (10 %)	Approved, Investigational	26833677
DrugRepV_0275	Nalidixic Acid	Antiinfectives For Systemic Use	Bacterial infections	Influenza virus	A/Brisbane/59/2007		Plaque assay	No significant effect	Approved, Investigational	26833677
DrugRepV_0280	Dorzolamide	Sensory Organ	Open-angle glaucoma and ocular hypertension	Influenza virus	A/New Jersey/15/2007		Plaque assay	Decrease (10 %)	Approved	26833677
DrugRepV_0281	Dorzolamide	Sensory Organ	Open-angle glaucoma and ocular hypertension	Influenza virus	A/Brisbane/59/2007		Plaque assay	No significant effect (NA %)	Approved	26833677
DrugRepV_0574	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Crimean-Congo hemorrhagic fever virus	IbAr10200, Nigeria	NA	Plaque assay	Decrease (50 %)	Approved	25796972
DrugRepV_0575	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Crimean-Congo hemorrhagic fever virus	ArD39554	NA	Plaque assay	Decrease (50 %)	Approved	25796972
DrugRepV_0576	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Crimean-Congo hemorrhagic fever virus	IbAr10200, Nigeria	NA	Plaque assay	Decrease (50 %)	Approved	25796972
DrugRepV_0577	Chlorpromazine	Nervous System	Schizophrenia	Crimean-Congo hemorrhagic fever virus	IbAr10200, Nigeria	NA	Plaque assay	Decrease (50 %)	Approved	25796972
DrugRepV_0578	Chlorpromazine	Nervous System	Schizophrenia	Crimean-Congo hemorrhagic fever virus	ArD39554	NA	Plaque assay	Decrease (50 %)	Approved	25796972
DrugRepV_0579	Chlorpromazine	Nervous System	Schizophrenia	Crimean-Congo hemorrhagic fever virus	IbAr10200, Nigeria	NA	Plaque assay	Decrease (50 %)	Approved	25796972
DrugRepV_0580	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever \| Typhus fever and the typhus group \| Q fever \| Rickettsial pox \| tick fevers caused by Rickettsiae \| Upper respiratory tract infections caused by Streptococcus pneumoniae	Influenza virus	Anhui01		Plaque assay	Decrease (1.3 Log10 copies)	Approved, Investigational	24496798
DrugRepV_0744	Favipiravir	Antiviral	Influenza virus	Nipah virus	NiV-Malaysia	NA	Plaque assay	Decrease (50 %)	Investigational	29765101
DrugRepV_0745	Favipiravir	Antiviral	Influenza virus	Hendra virus	Prototype	NA	Plaque assay	Decrease (50 %)	Investigational	29765101
DrugRepV_0746	Favipiravir	Antiviral	Influenza virus	Nipah virus	NiV-Bangladesh	NA	Plaque assay	Decrease (50 %)	Investigational	29765101
DrugRepV_0747	Favipiravir	Antiviral	Influenza virus	Nipah virus	rNiV-Gluc-eGFP	NA	Plaque assay	Decrease (50 %)	Investigational	29765101
DrugRepV_1583	Sorafenib	Antineoplastic and Immunomodulating Agents	Hepatocellular carcinoma \| Renal cell carcinoma	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (2 to 3 Logs reduction)	Approved, Investigational	26217313
DrugRepV_1584	Sorafenib	Antineoplastic and Immunomodulating Agents	Hepatocellular carcinoma \| Renal cell carcinoma	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (2 to 3 Logs reduction)	Approved, Investigational	26217313
DrugRepV_1585	Sorafenib	Antineoplastic and Immunomodulating Agents	Hepatocellular carcinoma \| Renal cell carcinoma	Rift Valley fever virus	rZH548	NA	Plaque assay	Decrease (4 Logs reduction)	Approved, Investigational	26217313
DrugRepV_1587	Sorafenib	Antineoplastic and Immunomodulating Agents	Hepatocellular carcinoma \| Renal cell carcinoma	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (50 %)	Approved, Investigational	26217313
DrugRepV_1591	Sorafenib	Antineoplastic and Immunomodulating Agents	Hepatocellular carcinoma \| Renal cell carcinoma	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (3 Logs reduction)	Approved, Investigational	26217313
DrugRepV_1592	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (4 Logs reduction)	Approved	26217313
DrugRepV_1593	Sorafenib	Antineoplastic and Immunomodulating Agents	Hepatocellular carcinoma \| Renal cell carcinoma	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (4.5 Logs reduction)	Approved, Investigational	26217313
DrugRepV_1594	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (4.5 Logs reduction)	Approved	26217313
DrugRepV_1595	Sorafenib	Antineoplastic and Immunomodulating Agents	Hepatocellular carcinoma \| Renal cell carcinoma	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (1 Logs reduction)	Approved, Investigational	26217313
DrugRepV_1596	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (1 Logs reduction)	Approved	26217313
DrugRepV_1597	Sorafenib	Antineoplastic and Immunomodulating Agents	Hepatocellular carcinoma \| Renal cell carcinoma	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (4 Logs reduction)	Approved, Investigational	26217313
DrugRepV_1598	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (3 Logs reduction)	Approved	26217313
DrugRepV_1599	Sorafenib	Antineoplastic and Immunomodulating Agents	Hepatocellular carcinoma \| Renal cell carcinoma	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (5 Logs reduction)	Approved, Investigational	26217313
DrugRepV_1600	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (4 Logs reduction)	Approved	26217313
DrugRepV_1601	Sorafenib	Antineoplastic and Immunomodulating Agents	Hepatocellular carcinoma \| Renal cell carcinoma	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (3 Logs reduction)	Approved, Investigational	26217313
DrugRepV_1602	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (6 Logs reduction)	Approved	26217313
DrugRepV_1603	Sorafenib	Antineoplastic and Immunomodulating Agents	Hepatocellular carcinoma \| Renal cell carcinoma	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (2 Logs reduction)	Approved, Investigational	26217313
DrugRepV_1604	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (2 Logs reduction)	Approved	26217313
DrugRepV_1605	Sorafenib	Antineoplastic and Immunomodulating Agents	Hepatocellular carcinoma \| Renal cell carcinoma	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (4 Logs reduction)	Approved, Investigational	26217313
DrugRepV_1606	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (5 Logs reduction)	Approved	26217313
DrugRepV_1607	Sorafenib	Antineoplastic and Immunomodulating Agents	Hepatocellular carcinoma \| Renal cell carcinoma	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (93 %)	Approved, Investigational	26217313
DrugRepV_1608	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (100 %)	Approved	26217313
DrugRepV_1609	Sorafenib	Antineoplastic and Immunomodulating Agents	Hepatocellular carcinoma \| Renal cell carcinoma	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (97 %)	Approved, Investigational	26217313
DrugRepV_1614	Sorafenib	Antineoplastic and Immunomodulating Agents	Hepatocellular carcinoma \| Renal cell carcinoma	Rift Valley fever virus	ZH501	NA	Plaque assay	Decrease (1.9 Logs reduction)	Approved, Investigational	26217313
DrugRepV_1882	PHA-690509	NA	Cancer	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Plaque assay	Decrease (50 %)	NA	27571349
DrugRepV_1883	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections \| Helminthiasis	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Plaque assay	Decrease (50 %)	Approved	27571349
DrugRepV_1913	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	PLCal_ZV	NA	Plaque assay	Decrease (50 %)	Approved	29315671
DrugRepV_1914	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	PLCal_ZV	NA	Plaque assay	Decrease (50 %)	Approved	29315671
DrugRepV_1915	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	PLCal_ZV	NA	Plaque assay	Decrease (50 %)	Approved	29315671
DrugRepV_1925	Manidipine	Cardiovascular agents	Hypertension	Influenza virus	PR/8/34		Plaque assay	No significant effect (50 %)	Approved, Investigational	29274844
DrugRepV_1926	Manidipine	Cardiovascular agents	Hypertension	Zika virus	H/PF/2013	NA	Plaque assay	Decrease (100 %)	Approved, Investigational	28814523
DrugRepV_1927	Cilnidipine	Cardiovascular agents	Hypertension	Zika virus	H/PF/2013	NA	Plaque assay	Decrease (100 %)	Approved	28814523
DrugRepV_1928	Benidipine Hydrochloride	Cardiovascular agents	Hypertension	Zika virus	H/PF/2013	NA	Plaque assay	Decrease (3 Logs)	Approved	28814523
DrugRepV_1929	Pimecrolimus	Dermatologicals	Atopic dermatitis	Zika virus	H/PF/2013	NA	Plaque assay	Decrease (2 Logs)	Approved, Investigational	28814523
DrugRepV_1930	Nelfinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	H/PF/2013	NA	Plaque assay	Decrease (2 Logs)	Approved	28814523
DrugRepV_1941	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Zika virus	SZ-WIV01	NA	Plaque assay	Decrease (>100 Fold)	Approved, Investigational, Vet approved	28480282
DrugRepV_1952	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Zika virus	SZ-WIV01	NA	Plaque assay	Decrease (100 %)	Approved, Investigational, Vet approved	28480282
DrugRepV_1964	Sorafenib	Antineoplastic and Immunomodulating Agents	Hepatocellular carcinoma \| Renal cell carcinoma	Rift Valley fever virus	MP12	NA	Plaque assay	Decrease (70 %)	Approved, Investigational	28794043
DrugRepV_1965	Fenretinide-Butylated Hydroxyanisole	NA	NA	Influenza virus	Strain A/PR8/ 34		Plaque assay	No significant effect	Investigational	25313218
DrugRepV_1966	Lanatoside C	Cardiovascular agents	Arrhythmia	Chikungunya virus	NA	NA	Plaque assay	Decrease (38.66 %)	Experimental	25251726
DrugRepV_2107	NITD008	Antiviral	NA	Zika virus	GZ01/2016	NA	Plaque assay	Decrease (50 %)	NA	27747251
DrugRepV_2108	NITD008	Antiviral	NA	Zika virus	FSS13025/2010	NA	Plaque assay	Decrease (50 %)	NA	27747251
DrugRepV_2113	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus \| Acquired immunodeficiency syndrome	Zika virus	PRVABC-59	NA	Plaque assay	Decrease (50 %)	Approved	27902933
DrugRepV_2114	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus \| Acquired immunodeficiency syndrome	Zika virus	PRVABC-59	NA	Plaque assay	Decrease (50 %)	Approved	27902933
DrugRepV_2115	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus \| Acquired immunodeficiency syndrome	Zika virus	Paraiba	NA	Plaque assay	Decrease (50 %)	Approved	27902933
DrugRepV_2116	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus \| Acquired immunodeficiency syndrome	Zika virus	Paraiba	NA	Plaque assay	Decrease (50 %)	Approved	27902933
DrugRepV_2117	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus \| Acquired immunodeficiency syndrome	Zika virus	Dakar	NA	Plaque assay	Decrease (50 %)	Approved	27902933
DrugRepV_2118	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus \| Acquired immunodeficiency syndrome	Zika virus	Dakar	NA	Plaque assay	Decrease (50 %)	Approved	27902933
DrugRepV_2136	7-deaza-2-C-methyl-D-adenosine	NA	Viral infection	Zika virus	MR766	NA	Plaque assay	Decrease (50 %)	NA	27163257
DrugRepV_2942	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	DRDE-06	NA	Plaque assay	Decrease (3 logs)	Approved	20336760
DrugRepV_2943	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	DRDE-06	NA	Plaque assay	Decrease (3 logs)	Approved	20336760
DrugRepV_2944	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	DRDE-06	NA	Plaque assay	Decrease (3 logs)	Approved	20336760
DrugRepV_2945	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	DRDE-06	NA	Plaque assay	Decrease (94 %)	Approved	20336760
DrugRepV_2946	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	DRDE-06	NA	Plaque assay	Decrease (65 %)	Approved	20336760
DrugRepV_2947	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	DRDE-06	NA	Plaque assay	Decrease (70 %)	Approved	20336760
DrugRepV_2952	Tetracycline	Antiinfectives For Systemic Use	Bacterial infections (Rocky Mountain spotted fever \| Typhus fever \| Tick fevers \| Q fever \| Rickettsialpox \| Brill-Zinsser disease)	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (2.76 �� 10⁷ pfu/ml)	Approved	25970853
DrugRepV_2953	Doxycycline	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (1.50 �� 10⁷ pfu/ml)	Approved	25970853
DrugRepV_2954	Rolitetracycline	Antiinfectives For Systemic Use	Bacterial infection	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (3.76 �� 10⁷ pfu/ml)	Approved	25970853
DrugRepV_2955	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (0.96 �� 10⁷ pfu/ml)	Approved	25970853
DrugRepV_2956	Aciclovir	Antiinfectives For Systemic Use	Viral infection	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (2.30 �� 10⁷ pfu/ml)	Approved	25970853
DrugRepV_2965	Doxycycline	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (68 %)	Approved	25970853
DrugRepV_2966	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (45 %)	Approved	25970853
DrugRepV_2967	Doxycycline-Ribavirin	NA	NA	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (91 %)	Approved	25970853
DrugRepV_2968	Doxycycline	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (71 %)	Approved	25970853
DrugRepV_2969	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (44 %)	Approved	25970853
DrugRepV_2970	Doxycycline-Ribavirin	NA	NA	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (92 %)	Approved	25970853
DrugRepV_2971	Doxycycline	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (43 %)	Approved	25970853
DrugRepV_2972	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (67 %)	Approved	25970853
DrugRepV_2973	Doxycycline-Ribavirin	NA	NA	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (91 %)	Approved	25970853
DrugRepV_2995	Flavaglines FL3	Anticancer	NA	Chikungunya virus	NA	NA	Plaque assay	Decrease (45 %)	NA	25643977
DrugRepV_2996	Flavaglines FL3	Anticancer	NA	Chikungunya virus	NA	NA	Plaque assay	Decrease (50 %)	NA	25643977
DrugRepV_2997	Flavaglines FL23	Anticancer	NA	Chikungunya virus	NA	NA	Plaque assay	Decrease (25 %)	NA	25643977
DrugRepV_2998	Flavaglines FL23	Anticancer	NA	Chikungunya virus	NA	NA	Plaque assay	Decrease (40 %)	NA	25643977
DrugRepV_2999	Sulfonyl Amidine	NA	NA	Chikungunya virus	NA	NA	Plaque assay	Decrease (10 %)	NA	25643977
DrugRepV_3000	Sulfonyl Amidine	NA	NA	Chikungunya virus	NA	NA	Plaque assay	Decrease (40 %)	NA	25643977
DrugRepV_3001	Flavaglines FL3	Anticancer	NA	Chikungunya virus	NA	NA	Plaque assay	Decrease (50 %)	NA	25643977
DrugRepV_3003	Imipramine	Nervous System	Depression	Chikungunya virus	La Reunion strain	NA	Plaque assay	Decrease (100 %)	Approved	28600536
DrugRepV_3010	Imipramine	Nervous System	Depression	Zika virus	Pf13	NA	Plaque assay	Decrease (100 %)	Approved	28600536
DrugRepV_3011	Curcumin	NA	Cancer, mucositis, chronic schizophrenia and mild cognitive impairment	Zika virus	HD78788	NA	Plaque assay	Decrease (75 %)	Approved	28343845
DrugRepV_3020	Demethoxycurcumin	NA	NA	Zika virus	HD78788	NA	Plaque assay	Decrease	Phase II	28343845
DrugRepV_3021	Bisdemethoxycurcumin	Plant extract	NA	Zika virus	HD78788	NA	Plaque assay	Decrease	Early Phase I	28343845
DrugRepV_3022	EF-24	NA	NA	Zika virus	HD78788	NA	Plaque assay	Decrease	NA	28343845
DrugRepV_3023	FLLL31	NA	NA	Zika virus	HD78788	NA	Plaque assay	Decrease	NA	28343845
DrugRepV_3024	Demethoxycurcumin	NA	NA	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Plaque assay	Decrease	Phase II	28343845
DrugRepV_3025	Bisdemethoxycurcumin	Plant extract	NA	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Plaque assay	Decrease	Early Phase I	28343845
DrugRepV_3026	EF-24	NA	NA	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Plaque assay	Decrease	NA	28343845
DrugRepV_3027	FLLL31	NA	NA	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Plaque assay	Decrease	NA	28343845
DrugRepV_3028	Demethoxycurcumin	NA	NA	Zika virus	HD78788	NA	Plaque assay	Decrease (50 %)	Phase II	28343845
DrugRepV_3029	Bisdemethoxycurcumin	Plant extract	NA	Zika virus	HD78788	NA	Plaque assay	Decrease (50 %)	Early Phase I	28343845
DrugRepV_3030	EF-24	NA	NA	Zika virus	HD78788	NA	Plaque assay	Decrease (50 %)	NA	28343845
DrugRepV_3031	FLLL31	NA	NA	Zika virus	HD78788	NA	Plaque assay	Decrease (50 %)	NA	28343845
DrugRepV_3032	Curcumin	NA	Cancer, mucositis, chronic schizophrenia and mild cognitive impairment	Zika virus	HD78788	NA	Plaque assay	Decrease (50 %)	Approved	28343845
DrugRepV_3033	Demethoxycurcumin	NA	NA	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Plaque assay	Decrease (50 %)	Phase II	28343845
DrugRepV_3034	Bisdemethoxycurcumin	Plant extract	NA	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Plaque assay	Decrease (50 %)	Early Phase I	28343845
DrugRepV_3035	EF-24	NA	NA	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Plaque assay	Decrease (50 %)	NA	28343845
DrugRepV_3036	FLLL31	NA	NA	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Plaque assay	Decrease (50 %)	NA	28343845
DrugRepV_3037	Curcumin	NA	Cancer, mucositis, chronic schizophrenia and mild cognitive impairment	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Plaque assay	Decrease (50 %)	Approved	28343845
DrugRepV_3076	Abamectin	NA	Helmintic infection	Chikungunya virus	CHIKV-Rluc	NA	Plaque assay	Decrease (3.5 Log)	Terminated	26752081
DrugRepV_3077	Berberine	NA	Parasitic and fungal infection	Chikungunya virus	CHIKV-Rluc	NA	Plaque assay	Decrease (5.2 Log)	Approved	26752081
DrugRepV_3078	Bromocriptine	Nervous System	Parkinson disease	Chikungunya virus	CHIKV-Rluc	NA	Plaque assay	No significant effect (No significant effect Log)	Approved	26752081
DrugRepV_3079	Cerivastatin	Cardiovascular agents	Rhabdomyolysis	Chikungunya virus	CHIKV-Rluc	NA	Plaque assay	No significant effect (No significant effect Log)	Approved	26752081
DrugRepV_3080	Fenretinide	Anticancer	Prostate cancer \| Breast cancer \| Macular degeneration	Chikungunya virus	CHIKV-Rluc	NA	Plaque assay	No significant effect (No significant effect Log)	Investigational	26752081
DrugRepV_3081	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis \| Onchocerciasis	Chikungunya virus	CHIKV-Rluc	NA	Plaque assay	Decrease (3.5 Log)	Approved, Investigational, Vet approved	26752081
DrugRepV_3082	Abamectin	NA	Helmintic infection	Chikungunya virus	NA	NA	Plaque assay	Decrease (2 Log)	Terminated	26752081
DrugRepV_3083	Berberine	NA	Parasitic and fungal infection	Chikungunya virus	NA	NA	Plaque assay	Decrease (3.3 Log)	Approved	26752081
DrugRepV_3084	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis \| Onchocerciasis	Chikungunya virus	NA	NA	Plaque assay	Decrease (3 Log)	Approved, Investigational, Vet approved	26752081
DrugRepV_3085	Abamectin	NA	Helmintic infection	Chikungunya virus	NA	NA	Plaque assay	Decrease (0.3 Log)	Terminated	26752081
DrugRepV_3086	Berberine	NA	Parasitic and fungal infection	Chikungunya virus	NA	NA	Plaque assay	Decrease (1.2 Log)	Approved	26752081
DrugRepV_3087	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis \| Onchocerciasis	Chikungunya virus	NA	NA	Plaque assay	Decrease (0.2 Log)	Approved, Investigational, Vet approved	26752081
DrugRepV_3132	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (50 %)	NA	23275491
DrugRepV_3133	Hypocrellin A	NA	NA	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (50 %)	NA	23275491
DrugRepV_3134	Rottlerin	NA	NA	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (50 %)	NA	23275491
DrugRepV_3135	Daunorubicin	Antineoplastic and Immunomodulating Agents	Leukemia	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (50 %)	Approved	23275491
DrugRepV_3136	Harringtonine	NA	NA	Chikungunya virus	CHIKV-122508	NA	Plaque assay	Decrease (4.3 Log)	NA	23275491
DrugRepV_3137	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (2.3 Log)	NA	23275491
DrugRepV_3138	Homoharringtonine	Antineoplastic and Immunomodulating Agents	Chronic myeloid leukemia (CML)	Chikungunya virus	CHIKV-122508	NA	Plaque assay	Decrease (4.3 Log)	Approved, Investigational	23275491
DrugRepV_3139	Homoharringtonine	Antineoplastic and Immunomodulating Agents	Chronic myeloid leukemia (CML)	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (2.3 Log)	Approved, Investigational	23275491
DrugRepV_3140	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (3 Log)	NA	23275491
DrugRepV_3141	Harringtonine	NA	NA	Chikungunya virus	CHIKV-122508	NA	Plaque assay	Decrease (3.5 Log)	NA	23275491
DrugRepV_3142	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (2.8 Log)	NA	23275491
DrugRepV_3143	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (7.8 Log)	NA	23275491
DrugRepV_3144	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (6.4 Log)	NA	23275491
DrugRepV_3178	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Chikungunya virus	DRDE-06	NA	Plaque assay	Decrease	Approved	21070810
DrugRepV_3181	Arbidol	NA	Viral infection	Influenza virus	A/Aichi/2/68		Plaque assay	Decrease (50 %)	Investigational	22028179
DrugRepV_3182	Arbidol	NA	Viral infection	Influenza virus	B/Beijing/184/93		Plaque assay	Decrease (50 %)	Investigational	22028179
DrugRepV_3183	Arbidol	NA	Viral infection	Influenza virus	A/Mem Bel		Plaque assay	Decrease (50 %)	Investigational	22028179
DrugRepV_3184	Arbidol	NA	Viral infection	Influenza virus	A/Queensland/6/72		Plaque assay	Decrease (50 %)	Investigational	22028179
DrugRepV_3185	Arbidol	NA	Viral infection	Influenza virus	A/Sydney/5/ 97		Plaque assay	Decrease (50 %)	Investigational	22028179
DrugRepV_3186	Arbidol	NA	Viral infection	Influenza virus	A/Moscow/16/98		Plaque assay	Decrease (50 %)	Investigational	22028179
DrugRepV_3187	Arbidol	NA	Viral infection	Influenza virus	A/PR/8/34		Plaque assay	Decrease (50 %)	Investigational	22028179
DrugRepV_3188	Arbidol	NA	Viral infection	Influenza virus	A/Moscow/17/98		Plaque assay	Decrease (50 %)	Investigational	22028179
DrugRepV_3189	Amantadine	Nervous System	Influenza and Parkinson Disease	Influenza virus	A/Aichi/2/68		Plaque assay	Decrease (50 %)	Approved	22028179
DrugRepV_3190	Rimantadine	Antiinfectives For Systemic Use	Influenza A virus	Influenza virus	A/Aichi/2/68		Plaque assay	Decrease (50 %)	Approved, Investigational	22028179
DrugRepV_3191	Arbidol	NA	Viral infection	Influenza virus	A/Aichi/2/68		Plaque assay	Decrease (Decrease (0.5-1.0) log)	Investigational	22028179
DrugRepV_3192	Amantadine	Nervous System	Influenza and Parkinson Disease	Influenza virus	A/Aichi/2/68		Plaque assay	No significant reduction (No significant reduction log)	Approved	22028179
DrugRepV_3193	Rimantadine	Antiinfectives For Systemic Use	Influenza A virus	Influenza virus	A/Aichi/2/68		Plaque assay	No significant reduction (No significant reduction log)	Approved, Investigational	22028179
DrugRepV_3197	Arbidol	NA	Viral infection	Influenza virus	A/Aichi/2/68		Plaque assay	Decrease (2.5 log)	Investigational	22028179
DrugRepV_3198	Arbidol	NA	Viral infection	Influenza virus	A/Aichi/2/68		Plaque assay	Decrease (3.73 log)	Investigational	22028179
DrugRepV_3199	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Plaque assay	No significant effect (No significant reduction log)	Investigational	26384169
DrugRepV_3201	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (3 Log)	Investigational	26384169
DrugRepV_3202	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Plaque assay	Decrease (2 Log)	Investigational	26384169
DrugRepV_3203	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (50 %)	Investigational	26384169
DrugRepV_3204	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Plaque assay	Decrease (50 %)	Investigational	26384169
DrugRepV_3216	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Plaque assay	Decrease (1 Log)	Investigational	26384169
DrugRepV_3217	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Plaque assay	Decrease (2 Log)	Investigational	26384169
DrugRepV_3218	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Plaque assay	Decrease (1.8 Log)	Investigational	26384169
DrugRepV_3219	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	No significant effect (No significant reduction Log)	Investigational	26384169
DrugRepV_3220	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (1 Log)	Investigational	26384169
DrugRepV_3221	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (0.9 Log)	Investigational	26384169
DrugRepV_3222	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (No significant reduction Log)	Investigational	26384169
DrugRepV_3223	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (1.2 Log)	Investigational	26384169
DrugRepV_3224	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (1.2 Log)	Investigational	26384169
DrugRepV_3229	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VS	NA	Plaque assay	Decrease (1.3 Log)	Investigational	26384169
DrugRepV_3230	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (2.5 Log)	Investigational	26384169
DrugRepV_3231	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (2 Log)	Investigational	26384169
DrugRepV_3233	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (50 %)	Investigational	26384169
DrugRepV_3243	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Indian Ocean strain 899	NA	Plaque assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3244	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	LR2006 OPY1	NA	Plaque assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3245	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Venturini (Italy 2008)	NA	Plaque assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3246	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Bianchi (Italy 2008)	NA	Plaque assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3247	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Congo 95 (2011)	NA	Plaque assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3248	T-1105	NA	Zika virus	Chikungunya virus	Indian Ocean strain 899	NA	Plaque assay	Decrease (50 %)	NA	24951535
DrugRepV_3312	TIvozanib	NA	Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease	Chikungunya virus	C21	NA	Plaque assay	No significant reduction (0.9 Log)	Investigational	27177310
DrugRepV_3313	TIvozanib	NA	Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease	Chikungunya virus	C21	NA	Plaque assay	Decrease (1.2 Log)	Investigational	27177310
DrugRepV_3314	TIvozanib	NA	Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease	Chikungunya virus	C21	NA	Plaque assay	No significant reduction (0.8 Log)	Investigational	27177310
DrugRepV_3315	Pimozide	Nervous System	Tourette Disorder	Chikungunya virus	C21	NA	Plaque assay	No significant reduction (0.5 Log)	Approved	27177310
DrugRepV_3316	5-Tetradecyloxy-2-furoic Acid	NA	NA	Chikungunya virus	C21	NA	Plaque assay	No significant reduction (0.2 Log)	NA	27177310
DrugRepV_3324	Naproxen	Musculo-Skeletal System	Rheumatoid arthritis \| Osteoarthritis \| Ankylosing spondylitis \| Polyarticular juvenile idiopathic arthritis \| Tendinitis \| Bursitis \| Acute gout \| Primary dysmenorrhea	Influenza virus	A/WSN/33		Plaque assay	Decrease (50 %)	Approved	23459490
DrugRepV_3326	Naproxen	Musculo-Skeletal System	Rheumatoid arthritis \| Osteoarthritis \| Ankylosing spondylitis \| Polyarticular juvenile idiopathic arthritis \| Tendinitis \| Bursitis \| Acute gout \| Primary dysmenorrhea	Influenza virus	A/WSN/33		Plaque assay	Decrease (2.5 Log)	Approved	23459490
DrugRepV_3327	Naproxen	Musculo-Skeletal System	Rheumatoid arthritis \| Osteoarthritis \| Ankylosing spondylitis \| Polyarticular juvenile idiopathic arthritis \| Tendinitis \| Bursitis \| Acute gout \| Primary dysmenorrhea	Influenza virus	UDORN/72		Plaque assay	Decrease (2.5 Log)	Approved	23459490
DrugRepV_3328	Naproxen	Musculo-Skeletal System	Rheumatoid arthritis \| Osteoarthritis \| Ankylosing spondylitis \| Polyarticular juvenile idiopathic arthritis \| Tendinitis \| Bursitis \| Acute gout \| Primary dysmenorrhea	Influenza virus	A/PR8		Plaque assay	Decrease (1.5 Log)	Approved	23459490
DrugRepV_3329	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	WSN/H1N1		Plaque assay	Decrease (99 %)	Approved	29990517
DrugRepV_3330	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	FPV/H7N7		Plaque assay	Decrease (99 %)	Approved	29990517
DrugRepV_3331	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	RB1/H1N1pdm09		Plaque assay	Decrease (50 %)	Approved	29990517
DrugRepV_3332	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	PR8M/H1N1		Plaque assay	No significant effect (0.3 Log)	Approved	29990517
DrugRepV_3333	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	Victoria/H3N2		Plaque assay	Decrease (1.2 Log)	Approved	29990517
DrugRepV_3334	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	FPV/H7N7		Plaque assay	Decrease (1 Log)	Approved	29990517
DrugRepV_3335	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	WSN/H1N1		Plaque assay	Decrease (98 %)	Approved	29990517
DrugRepV_3336	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	Victoria/H3N2		Plaque assay	Decrease (76 %)	Approved	29990517
DrugRepV_3337	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	FPV/H7N7		Plaque assay	Decrease (80 %)	Approved	29990517
DrugRepV_3338	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	WSN/H1N1		Plaque assay	No significant effect (0.8 Log)	Approved	29990517
DrugRepV_3339	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	WSN/H1N1		Plaque assay	Decrease (70 %)	Approved	29990517
DrugRepV_3340	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	Victoria/H3N2		Plaque assay	Decrease (70 %)	Approved	29990517
DrugRepV_3341	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	FPV/H7N7		Plaque assay	Decrease (100 %)	Approved	29990517
DrugRepV_3342	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	WSN/H1N1		Plaque assay	No significant effect (0.8 Log)	Approved	29990517
DrugRepV_3343	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	Victoria/H3N2		Plaque assay	No significant effect (0.5 Log)	Approved	29990517
DrugRepV_3344	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	KAN-1/H5N1		Plaque assay	Decrease (98 %)	Approved	29990517
DrugRepV_3345	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	Mallard/H5N1		Plaque assay	Decrease (99 %)	Approved	29990517
DrugRepV_3346	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	SC35M/H7N7		Plaque assay	Decrease (90 %)	Approved	29990517
DrugRepV_3347	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	KAN-1/H5N1		Plaque assay	Decrease (1.2 Log)	Approved	29990517
DrugRepV_3348	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	SC35M/H7N7		Plaque assay	No significant effect (0.8 Log)	Approved	29990517
DrugRepV_3349	Oseltamivir	Antiinfectives For Systemic Use	Influenza A/B virus	Influenza virus	WSN/H1N1		Plaque assay	No significant effect (40 %)	Approved	29990517
DrugRepV_3350	Trametinib-Oseltamivir	NA	NA	Influenza virus	WSN/H1N1		Plaque assay	Decrease (95 %)	Approved	29990517
DrugRepV_3351	Oseltamivir	Antiinfectives For Systemic Use	Influenza A/B virus	Influenza virus	WSN/H1N1		Plaque assay	Decrease (1.5 Log)	Approved	29990517
DrugRepV_3352	Trametinib-Oseltamivir	NA	NA	Influenza virus	WSN/H1N1		Plaque assay	Decrease (3.5 Log)	Approved	29990517
DrugRepV_3353	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	RB1/H1N1pdm09		Plaque assay	Decrease (1.5 Log)	Approved	29990517
DrugRepV_3354	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	RB1/H1N1pdm09		Plaque assay	Decrease (98 %)	Approved	29990517
DrugRepV_3357	Naproxen	Musculo-Skeletal System	Rheumatoid arthritis \| Osteoarthritis \| Ankylosing spondylitis \| Polyarticular juvenile idiopathic arthritis \| Tendinitis \| Bursitis \| Acute gout \| Primary dysmenorrhea	Influenza virus	A/Udorn/72		Plaque assay	Decrease (50 %)	Approved	30028133
DrugRepV_3360	Naproxen	Musculo-Skeletal System	Rheumatoid arthritis \| Osteoarthritis \| Ankylosing spondylitis \| Polyarticular juvenile idiopathic arthritis \| Tendinitis \| Bursitis \| Acute gout \| Primary dysmenorrhea	Influenza virus	A/PR/8/34		Plaque assay	No significant effect (0.5 Log)	Approved	30028133
DrugRepV_3401	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (100 %)	Approved	24096239
DrugRepV_3402	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (100 %)	Approved	24096239
DrugRepV_3403	Rebif	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (100 %)	Approved	24096239
DrugRepV_3404	Intron A	Antineoplastic and Immunomodulating Agents	Hairy cell leukemia \| Malignant melanoma \| AIDS-related Kaposi's sarcoma	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (76.2 %)	Approved	24096239
DrugRepV_3405	Avonex	Antineoplastic and Immunomodulating Agents	Hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (70.2 %)	Approved	24096239
DrugRepV_3406	Betaferon	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (66.6 %)	Approved	24096239
DrugRepV_3407	SSYA10-001	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (50 %)	NA	24841268
DrugRepV_3408	SSYA10-001	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (50 %)	NA	24841268
DrugRepV_3409	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/California/07/2009 (H1N1)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3410	Etravirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Influenza virus	A/California/07/2009 (H1N1)		Plaque assay	Decrease (50 %)	Approved	28778830
DrugRepV_3411	Rilpivirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Influenza virus	A/California/07/2009 (H1N1)		Plaque assay	Decrease (50 %)	Approved	28778830
DrugRepV_3412	Oseltamivir	Antiinfectives For Systemic Use	Influenza A/B virus	Influenza virus	A/California/07/2009 (H1N1)		Plaque assay	Decrease (50 %)	Approved	28778830
DrugRepV_3413	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	B/Bris/60/2008 (Victoria)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3414	Etravirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Influenza virus	B/Bris/60/2008 (Victoria)		Plaque assay	Decrease (50 %)	Approved	28778830
DrugRepV_3415	Oseltamivir	Antiinfectives For Systemic Use	Influenza A/B virus	Influenza virus	B/Bris/60/2008 (Victoria)		Plaque assay	Decrease (50 %)	Approved	28778830
DrugRepV_3416	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/California/7/2009 (H1N1)		Plaque assay	Decrease (2.1 Log)	Investigational	28778830
DrugRepV_3417	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/California/7/2009 (H1N1)		Plaque assay	Decrease (2.9 Log)	Investigational	28778830
DrugRepV_3418	Oseltamivir	Antiinfectives For Systemic Use	Influenza A/B virus	Influenza virus	A/California/7/2009 (H1N1)		Plaque assay	Decrease (1.7 Log)	Approved	28778830
DrugRepV_3419	Oseltamivir	Antiinfectives For Systemic Use	Influenza A/B virus	Influenza virus	A/California/7/2009 (H1N1)		Plaque assay	Decrease (2 Log)	Approved	28778830
DrugRepV_3420	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/WSN/1933 (H1N1)		Plaque assay	Decrease (1.7 Log)	Investigational	28778830
DrugRepV_3421	Oseltamivir	Antiinfectives For Systemic Use	Influenza A/B virus	Influenza virus	A/WSN/1933 (H1N1)		Plaque assay	Decrease (1.4 Log)	Approved	28778830
DrugRepV_3422	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/DM/528/2009 (H1N1)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3423	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/Texas/4/2009 (H1N1)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3424	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/North Carolina/39/2009 (H1N1)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3425	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/Washington/29/2009 (H1N1)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3426	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/WSN/1933 (H1N1)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3427	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/California/07/2009 (H1N1)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3428	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/DM/524/2009 (H1N1)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3429	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/Switzerland/9715293/2013 (H3N2)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3430	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/Switzerland/9715293/2013 X-247 (H3N2)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3432	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/California/2/2014 (H3N2)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3433	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/Udorn/1972 (H3N2)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3434	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/Soloman Islands/3/2006 (H1N1)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3435	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	B/Wisconsin/1/2010 (Yamagata)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3436	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	B/Bris/60/2008 (Victoria)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3458	Hesperadin	Anticancer	NA	Influenza virus	A/Texas/4/2009 (H1N1)		Plaque assay	Decrease (50 %)	Approved, Investigational	28885544
DrugRepV_3459	Hesperadin	Anticancer	NA	Influenza virus	A/North Carolina/39/2009 (H1N1)		Plaque assay	Decrease (50 %)	Approved, Investigational	28885544
DrugRepV_3460	Hesperadin	Anticancer	NA	Influenza virus	A/Washington/29/2009 (H1N1)		Plaque assay	Decrease (50 %)	Approved, Investigational	28885544
DrugRepV_3461	Hesperadin	Anticancer	NA	Influenza virus	A/California/02/2014 (H3N2)		Plaque assay	Decrease (50 %)	Approved, Investigational	28885544
DrugRepV_3462	Hesperadin	Anticancer	NA	Influenza virus	A/Texas/12/2007 (H3N2)		Plaque assay	Decrease (50 %)	Approved, Investigational	28885544
DrugRepV_3463	Hesperadin	Anticancer	NA	Influenza virus	A/WSN/1933 (H1N1)		Plaque assay	Decrease (50 %)	Approved, Investigational	28885544
DrugRepV_3464	Hesperadin	Anticancer	NA	Influenza virus	A/California/07/2009 (H1N1)		Plaque assay	Decrease (50 %)	Approved, Investigational	28885544
DrugRepV_3465	Hesperadin	Anticancer	NA	Influenza virus	B/Wisconsin/1/2010 (Yamagata)		Plaque assay	Decrease (50 %)	Approved, Investigational	28885544
DrugRepV_3466	Hesperadin	Anticancer	NA	Influenza virus	B/brisbane/60/2008 (victoria)		Plaque assay	Decrease (50 %)	Approved, Investigational	28885544
DrugRepV_3467	Hesperadin	Anticancer	NA	Influenza virus	A/California/07/2009 (H1N1)		Plaque assay	Decrease (2.5 Log)	Approved, Investigational	28885544
DrugRepV_3468	Hesperadin	Anticancer	NA	Influenza virus	A/Washington/39/2009 (H1N1)		Plaque assay	Decrease (2.5 Log)	Approved, Investigational	28885544
DrugRepV_3469	Hesperadin	Anticancer	NA	Influenza virus	B/Wisconsin/1/2010 (Yamagata)		Plaque assay	Decrease (3.4 Log)	Approved, Investigational	28885544
DrugRepV_3557	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	181/clone 25	NA	Plaque assay	Decrease (50 %)	Approved	30354193
DrugRepV_3558	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	181/clone 25	NA	Plaque assay	Decrease (50 %)	Approved	30354193
DrugRepV_3559	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	181/clone 25	NA	Plaque assay	Decrease (50 %)	Approved	30354193
DrugRepV_3560	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	181/clone 25	NA	Plaque assay	Decrease (50 %)	Investigational	30354193
DrugRepV_3561	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	181/clone 25	NA	Plaque assay	Decrease (50 %)	Investigational	30354193
DrugRepV_3562	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	181/clone 25	NA	Plaque assay	Decrease (50 %)	Investigational	30354193
DrugRepV_3563	IFN-alpha2a	Antineoplastic and Immunomodulating Agentss	Hepatitis C virus \| Hairy cell leukemia \| AIDS-related Kaposi's sarcoma \| Leukemia	Chikungunya virus	181/clone 25	NA	Plaque assay	Decrease (50 %)	Approved, Investigational	30354193
DrugRepV_3564	IFN-alpha2a	Antineoplastic and Immunomodulating Agentss	Hepatitis C virus \| Hairy cell leukemia \| AIDS-related Kaposi's sarcoma \| Leukemia	Chikungunya virus	181/clone 25	NA	Plaque assay	Decrease (50 %)	Approved, Investigational	30354193
DrugRepV_3565	IFN-alpha2a	Antineoplastic and Immunomodulating Agentss	Hepatitis C virus \| Hairy cell leukemia \| AIDS-related Kaposi's sarcoma \| Leukemia	Chikungunya virus	181/clone 25	NA	Plaque assay	Decrease (50 %)	Approved, Investigational	30354193
DrugRepV_3883	UV-1	NA	NA	Ebola virus	Zaire-Kikwit	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3884	UV-2	NA	NA	Ebola virus	Zaire-Kikwit	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3885	UV-3	NA	NA	Ebola virus	Zaire-Kikwit	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3886	UV-4	NA	NA	Ebola virus	Zaire-Kikwit	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3887	UV-5	NA	NA	Ebola virus	Zaire-Kikwit	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3888	UV-1	NA	NA	Marburg virus	Ci67	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3889	UV-2	NA	NA	Marburg virus	Ci67	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3890	UV-3	NA	NA	Marburg virus	Ci67	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3891	UV-4	NA	NA	Marburg virus	Ci67	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3892	UV-5	NA	NA	Marburg virus	Ci67	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3938	GSK983	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3939	Angelicin	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3940	Benzoquinoline	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3941	SW539	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3942	SW320	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3943	SW351	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3944	SW491	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3945	SW490	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3946	SW388	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3947	SW386	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3948	SW349	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3949	SW991	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3950	SW456	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_4001	FGI-103	NA	NA	Ebola virus	Zaire	NA	Plaque assay	Decrease (50 %)	NA	20211898
DrugRepV_4002	FGI-103	NA	NA	Ebola virus	Sudan	NA	Plaque assay	Decrease (50 %)	NA	20211898
DrugRepV_4003	FGI-103	NA	NA	Marburg virus	Ravn	NA	Plaque assay	Decrease (50 %)	NA	20211898
DrugRepV_4004	FGI-103	NA	NA	Marburg virus	Ci67	NA	Plaque assay	Decrease (95 %)	NA	20211898
DrugRepV_4318	FGI-106	NA	NA	Ebola virus	Zaire	NA	Plaque assay	Decrease (50 %)	NA	19523489
DrugRepV_4319	FGI-106	NA	NA	Rift Valley fever virus	MP12	NA	Plaque assay	Decrease (50 %)	NA	19523489
DrugRepV_4648	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus \| Acquired immunodeficiency syndrome	Zika virus	NA	NA	Plaque assay	Decrease (50 %)	Approved	28098253
DrugRepV_4649	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	NA	NA	Plaque assay	Decrease (50 %)	Approved	28098253
DrugRepV_4650	IFN-alpha	Antiviral	Hepatitis C virus \| Leukemia \| Melanoma	Zika virus	NA	NA	Plaque assay	Decrease (50 %)	Investigational	28098253
DrugRepV_4651	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus \| Acquired immunodeficiency syndrome	Zika virus	NA	NA	Plaque assay	Decrease (1.00E+02 pfu/ml)	Approved	28098253
DrugRepV_4652	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus \| Acquired immunodeficiency syndrome	Zika virus	NA	NA	Plaque assay	Decrease (5.00E+07 pfu/ml)	Approved	28098253
DrugRepV_4681	N-(4-hydroxyphenyl) retinamide	NA	NA	Zika virus	MR766	NA	Plaque assay	Decrease (90 %)	Investigational	29051080
DrugRepV_4711	Quinacrine	NA	Malaria \| Giardiasis \| Cutaneous leishmaniasis \| Management of malignant effusions	Zika virus	MR766	NA	Plaque assay	Decrease (50 %)	Investigational	27889529
DrugRepV_4712	Mefloquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	MR766	NA	Plaque assay	Decrease (50 %)	Approved, Investigational	27889529
DrugRepV_4713	GSK369796	NA	NA	Zika virus	MR766	NA	Plaque assay	Decrease (50 %)	NA	27889529
DrugRepV_4729	L-NAME	NA	Hypotension \| Spinal Cord Injury	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (15 %)	Investigational	25487801
DrugRepV_4730	AG490	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (17 %)	NA	25487801
DrugRepV_4731	PKC-412	NA	Acute myeloid leukemia	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (33 %)	Approved, Investigational	25487801
DrugRepV_4732	Ro 31-8220	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (73 %)	NA	25487801
DrugRepV_4733	GF109203X	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (53 %)	NA	25487801
DrugRepV_4734	SB203580	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (45 %)	NA	25487801
DrugRepV_4735	U0126	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (50 %)	NA	25487801
DrugRepV_4736	Wortmannin	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (40 %)	Experimental	25487801
DrugRepV_4737	Rapamycin	Antineoplastic and Immunomodulating Agents; Sensory Organ	Prophylaxis of organ rejection in patients receiving renal transplants	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (60 %)	Approved, Investigational	25487801
DrugRepV_4738	Bay 11-7082	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (28 %)	NA	25487801
DrugRepV_4739	GW5074	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (50 %)	NA	25487801
DrugRepV_4740	PP2	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (23 %)	NA	25487801
DrugRepV_4741	Sorafenib	Antineoplastic and Immunomodulating Agents	Hepatocellular carcinoma \| Renal cell carcinoma	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (93 %)	Approved, Investigational	25487801
DrugRepV_4742	Everolimus	Antineoplastic and Immunomodulating Agents	Immune disorders	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (57 %)	Approved	25487801
DrugRepV_4743	Dabrafenib	Antineoplastic and Immunomodulating Agents	Melanoma	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (50 %)	Approved	25487801
DrugRepV_4744	Selumetinib	Anticancer	Melanoma \| Solid Tumour \| Breast Cancer \| Non Small Cell Lung Cancer	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (70 %)	Investigational	25487801
DrugRepV_4745	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (95 %)	Approved	25487801
DrugRepV_4746	Miltefosine	Antineoplastic and Immunomodulating Agents	Visceral leishmaniasis	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (28 %)	Approved	25487801
DrugRepV_4771	sodium (2S)-2-[(2S)-2-{[({1-[(tert-butoxy)carbonyl]piperidin-4-yl}oxy)carbonyl]amino}-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (50 %)	NA	29544147
DrugRepV_4772	sodium (2S)-2-[(2S)-2-{[({4-benzyl-1-[(tert-butoxy)carbonyl]piperidin-4-yl}oxy)carbonyl]amino}-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (50 %)	NA	29544147
DrugRepV_5083	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Crimean-Congo hemorrhagic fever virus	86-07	NA	Plaque assay	Decrease (50 %)	Approved	25796972
DrugRepV_5084	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Crimean-Congo hemorrhagic fever virus	86-07	NA	Plaque assay	Decrease (50 %)	Approved	25796972
DrugRepV_5085	Chlorpromazine	Antiinflammatory and antineoplastic	Schizophrenia	Crimean-Congo hemorrhagic fever virus	86-07	NA	Plaque assay	Decrease (50 %)	Approved	25796972
DrugRepV_5086	Chlorpromazine	Antiinflammatory and antineoplastic	Schizophrenia	Crimean-Congo hemorrhagic fever virus	87-07	NA	Plaque assay	Decrease (50 %)	Approved	25796972
DrugRepV_5087	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Crimean-Congo hemorrhagic fever virus	87-07	NA	Plaque assay	Decrease (50 %)	Approved	25796972
DrugRepV_5088	Chlorpromazine	Antiinflammatory and antineoplastic	Schizophrenia	Crimean-Congo hemorrhagic fever virus	87-07	NA	Plaque assay	Decrease (50 %)	Approved	25796972
DrugRepV_5150	PF-4708671	NA	NA	Rift Valley fever virus	MP12	NA	Plaque assay	No significant effect (0.5 log pfu/ml)	NA	29652799
DrugRepV_5152	PF-4708671-BI-D1870	NA	NA	Rift Valley fever virus	MP12	NA	Plaque assay	Decrease (2 log pfu/ml)	NA	29652799
DrugRepV_5154	SB203580	NA	NA	Rift Valley fever virus	MP12	NA	Plaque assay	No significant effect (<0.5log pfu/ml)	NA	29652799
DrugRepV_5156	PD0325901	NA	Melanoma \| Solid Tumour \| Solid Tumors \| Advanced Cancer \| Breast Neoplasms	Rift Valley fever virus	MP12	NA	Plaque assay	No significant effect (0.5log pfu/ml)	Investigational	29652799
DrugRepV_5157	Rapamycin	Antineoplastic and Immunomodulating Agents; Sensory Organ	Prophylaxis of organ rejection in patients receiving renal transplants	Rift Valley fever virus	MP12	NA	Plaque assay	Decrease (2log pfu/ml)	Approved, Investigational	29652799
DrugRepV_5158	Rapamycin-SB203580	NA	NA	Rift Valley fever virus	MP12	NA	Plaque assay	Decrease (>3log pfu/ml)	NA	29652799
DrugRepV_5159	Rapamycin-PD0325901	NA	NA	Rift Valley fever virus	MP12	NA	Plaque assay	Decrease (3log pfu/ml)	NA	29652799
DrugRepV_5167	Rapamycin	Antineoplastic and Immunomodulating Agents; Sensory Organ	Prophylaxis of organ rejection in patients receiving renal transplants	Rift Valley fever virus	MP12	NA	Plaque assay	Decrease (2 log pfu/ml)	Approved, Investigational	28442428
DrugRepV_5168	Rapamycin	Antineoplastic and Immunomodulating Agents; Sensory Organ	Prophylaxis of organ rejection in patients receiving renal transplants	Rift Valley fever virus	ZH501	NA	Plaque assay	Decrease (1 log pfu/ml)	Approved, Investigational	28442428
DrugRepV_5178	Suramin	Antiparasitic products, Insectisides and Repellents	Sleeping sickness \| Onchocerciasis	Rift Valley fever virus	MP12	NA	Plaque assay	Decrease	Investigational	25267680
DrugRepV_5179	Suramin	Antiparasitic products, Insectisides and Repellents	Sleeping sickness \| Onchocerciasis	Rift Valley fever virus	MP12	NA	Plaque assay	Decrease (50 %)	Investigational	25267680
DrugRepV_5207	Favipiravir	Antiviral	Influenza virus	Rift Valley fever virus	ZH501	NA	Plaque assay	Decrease	Investigational	24722586
DrugRepV_5208	Curcumin	NA	Depressive disorder	Rift Valley fever virus	MP12	NA	Plaque assay	Decrease (3 log pfu/ml)	Approved	22847000
DrugRepV_5209	SC-514	NA	NA	Rift Valley fever virus	MP12	NA	Plaque assay	Decrease (<1 log pfu/ml)	NA	22847000
DrugRepV_5210	Curcumin	NA	Depressive disorder	Rift Valley fever virus	ZH501	NA	Plaque assay	Decrease (4 log pfu/ml)	Approved	22847000
DrugRepV_5211	Curcumin	NA	Depressive disorder	Rift Valley fever virus	MP12	NA	Plaque assay	Decrease (5 log pfu/ml)	Approved	22847000
DrugRepV_5223	Actinomycin D	Antineoplastic and Immunomodulating Agents	Cancer	Rift Valley fever virus	rMP12-rLuc	NA	Plaque assay	Decrease (>2 log pfu/ml)	Approved	19197350
DrugRepV_5224	Actinomycin D	Antineoplastic and Immunomodulating Agents	Cancer	Rift Valley fever virus	MP12	NA	Plaque assay	No significant effect (NA pfu/ml)	Approved	19197350
DrugRepV_5252	Rifampicin	Antiinfectives For Systemic Use	Tuberculosis and Tuberculosis-related mycobacterial infections	Variola virus	Butler	NA	Plaque assay	Decrease (Complete inhibition Plaque size)	Approved	4321450
DrugRepV_5261	Delphinidin Chloride	NA	NA	Zika virus	MR766	NA	Plaque assay	Decrease (10² Log)	NA	28744282
DrugRepV_5262	Epigallocatechin Gallate	Cardiovascular agents	Hypertension and Diabetic Nephropathy	Zika virus	MR766	NA	Plaque assay	Decrease (4.3 x 10⁴ Log)	Investigational	28744282
DrugRepV_5263	Delphinidin Chloride	NA	NA	Zika virus	PA259459	NA	Plaque assay	Decrease	NA	28744282
DrugRepV_5264	Epigallocatechin Gallate	Cardiovascular agents	Hypertension and Diabetic Nephropathy	Zika virus	PA259459	NA	Plaque assay	Decrease	Investigational	28744282
DrugRepV_5265	Tetra-O-methyl nordihydroguaiaretic acid (M4N)	NA	Brain and Central Nervous System Tumors	Zika virus	PA259459	NA	Plaque assay	Decrease (50 %)	Investigational	28507114
DrugRepV_5266	Tetra-O-methyl nordihydroguaiaretic acid (M4N)	NA	Brain and Central Nervous System Tumors	Zika virus	PA259459	NA	Plaque assay	Decrease (50 %)	Investigational	28507114
DrugRepV_5454	Atovaquone	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	MR766	NA	Plaque assay	Decrease (2 log10PFU/ml)	Approved	30894466
DrugRepV_5455	Atovaquone	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	MR766	NA	Plaque assay	Decrease (5.5 log10PFU/ml)	Approved	30894466
DrugRepV_5456	Atovaquone	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	MR766	NA	Plaque assay	Decrease (2 log10PFU/ml)	Approved	30894466
DrugRepV_5471	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	FPV/H7N7		Plaque assay	No significant effect (2.5 Log)	Approved	29990517
DrugRepV_5472	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	Mallard/H5N1		Plaque assay	No significant effect (2 Log)	Approved	29990517
DrugRepV_5479	Beta-D-N4-hydroxycytidine	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (50 %)	NA	31578288
DrugRepV_5480	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis \| Onchocerciasis	Zika virus	(Asian/Cook Islands/2014	NA	Plaque assay	Decrease (50 %)	Approved, Investigational, Vet approved	32135219
DrugRepV_5482	RK-33	NA	NA	Zika virus	Asian/Cook Islands/2014	NA	Plaque assay	Decrease (50 %)	NA	31936642
DrugRepV_5525	Papaverine	Genito Urinary System and Sex Hormones	Impotence \| Vasospasms	Influenza virus	A/WSN/33		Plaque assay	Decrease (50 %)	Approved, Investigational	31896588
DrugRepV_5526	Papaverine	Genito Urinary System and Sex Hormones	Impotence \| Vasospasms	Influenza virus	B/Lee/40		Plaque assay	Decrease (50 %)	Approved, Investigational	31896588
DrugRepV_5527	Papaverine	Genito Urinary System and Sex Hormones	Impotence \| Vasospasms	Influenza virus	A/Udorn/72		Plaque assay	Decrease (50 %)	Approved, Investigational	31896588
DrugRepV_5528	Papaverine	Genito Urinary System and Sex Hormones	Impotence \| Vasospasms	Influenza virus	A/Equine/2/MIAMI/1/63		Plaque assay	Decrease (50 %)	Approved, Investigational	31896588
DrugRepV_5529	Papaverine	Genito Urinary System and Sex Hormones	Impotence \| Vasospasms	Influenza virus	A/PR/8/34		Plaque assay	Decrease (50 %)	Approved, Investigational	31896588
DrugRepV_5530	Papaverine	Genito Urinary System and Sex Hormones	Impotence \| Vasospasms	Influenza virus	B/MD/59		Plaque assay	Decrease (50 %)	Approved, Investigational	31896588
DrugRepV_5594	Sunitinib	Antineoplastic and Immunomodulating Agents	Renal cell carcinoma \| Gastrointestinal stromal tumor	Dengue virus	276RKI, PRS41393		Plaque assay	Decrease (50 %)	Approved, Investigational	28240606
DrugRepV_5595	Erlotinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	276RKI, PRS41393		Plaque assay	Decrease (50 %)	Approved	28240606
DrugRepV_5598	Sunitinib	Antineoplastic and Immunomodulating Agents	Renal cell carcinoma \| Gastrointestinal stromal tumor	Dengue virus	Philippines/H87/1956		Plaque assay	Decrease (50 %)	Approved, Investigational	28240606
DrugRepV_5599	Erlotinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	Philippines/H87/1956		Plaque assay	Decrease (50 %)	Approved	28240606
DrugRepV_5600	Sunitinib	Antineoplastic and Immunomodulating Agents	Renal cell carcinoma \| Gastrointestinal stromal tumor	Dengue virus	BC287/97, H241		Plaque assay	Decrease (50 %)	Approved, Investigational	28240606
DrugRepV_5601	Erlotinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	BC287/97, H241		Plaque assay	Decrease (50 %)	Approved	28240606
DrugRepV_5636	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV1-2402		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5637	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV2-3295		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5638	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV1-2402		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5639	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV2-3295		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5640	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV1-2402		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5641	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV2-3295		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5642	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV1-2402		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5643	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV2-3295		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5644	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	S221		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5645	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	S221		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5646	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	S221		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5647	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	S221		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5656	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	EDEN 872		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5657	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	EDEN 2402		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5658	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	PVP41		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5659	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	EDEN3300		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5660	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	EDEN2928		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5661	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	ST		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5662	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	EDEN 3295		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5663	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	PR8545		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5664	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	PR2167		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5665	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	PVP110		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5666	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	EDEN 863		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5667	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	EDEN 2930		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5668	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	EDEN 2270		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5669	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	EHI 69273		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5670	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	EHI 16693		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5671	Epoxomicin	Anti-inflammatory	Hypertension	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	26565697
DrugRepV_5672	Epoxomicin	Anti-inflammatory	Hypertension	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	26565697
DrugRepV_5673	Epoxomicin	Anti-inflammatory	Hypertension	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	26565697
DrugRepV_5674	Epoxomicin	Anti-inflammatory	Hypertension	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	26565697
DrugRepV_5704	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Dengue virus	16681		Plaque assay	Decrease (>1.0 + E3 pfu/ml)	Approved	12504563
DrugRepV_5707	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	TSV01		Plaque assay	No significant effect (<0.5 Log10 PFU/ml)	Phase II failed	24257621
DrugRepV_5708	R1479	NA	NA	Dengue virus	MY-10340		Plaque assay	Decrease (50 %)	NA	24257621
DrugRepV_5710	Sunitinib-Erlotinib	NA	NA	Dengue virus	NA		Plaque assay	Decrease (>5 Log (pfu/g))	NA	29753658
DrugRepV_5743	Telaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	DV2-NGC		Plaque assay	Decrease (50 %)	Approved	29297305
DrugRepV_5744	Asunaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	DV2-NGC		Plaque assay	Decrease (50 %)	Phase III	29297305
DrugRepV_5753	Fenretinide	Anticancer	Prostate cancer \| Breast cancer \| Macular degeneration	Dengue virus	NGC		Plaque assay	Decrease (1000 Fold)	Investigational	25313218
DrugRepV_5756	Fenretinide	Anticancer	Prostate cancer \| Breast cancer \| Macular degeneration	Dengue virus	NGC		Plaque assay	Decrease (50 %)	Investigational	25313218
DrugRepV_5757	Fenretinide	Anticancer	Prostate cancer \| Breast cancer \| Macular degeneration	Dengue virus	NGC		Plaque assay	Decrease (3.2 Logs)	Investigational	25313218
DrugRepV_5758	Fenretinide	Anticancer	Prostate cancer \| Breast cancer \| Macular degeneration	Dengue virus	NGC		Plaque assay	Decrease (1 Logs)	Investigational	25313218
DrugRepV_5759	Fenretinide	Anticancer	Prostate cancer \| Breast cancer \| Macular degeneration	Dengue virus	NGC		Plaque assay	Decrease (1 Logs)	Investigational	25313218
DrugRepV_5760	Fenretinide	Anticancer	Prostate cancer \| Breast cancer \| Macular degeneration	Dengue virus	NGC		Plaque assay	Decrease (0 Logs)	Investigational	25313218
DrugRepV_5761	Myriocin	NA	Bacterial infections	Dengue virus	NGC		Plaque assay	No significant effect	NA	25313218
DrugRepV_5762	Fenretinide-Myriocin	NA	NA	Dengue virus	NGC		Plaque assay	Decrease (4 Logs)	NA	25313218
DrugRepV_5763	Butylated Hydroxyanisole	NA	Antioxidant	Dengue virus	NGC		Plaque assay	No significant effect	NA	25313218
DrugRepV_5764	Fenretinide-Butylated Hydroxyanisole	NA	NA	Dengue virus	NGC		Plaque assay	Decrease (1.5 Logs)	NA	25313218
DrugRepV_5765	Vitamin C	Alimentary Tract and Metabolism	Vitamin C deficiency, scurvy, delayed wound and bone healing, urine acidification	Dengue virus	NGC		Plaque assay	No significant effect	Approved	25313218
DrugRepV_5766	Fenretinide-Vitamin C	NA	NA	Dengue virus	NGC		Plaque assay	Decrease (3 Logs)	NA	25313218
DrugRepV_5767	Fenretinide	Anticancer	Prostate cancer \| Breast cancer \| Macular degeneration	Dengue virus	D2Y98P		Plaque assay	Decrease (1.73 Logs)	Investigational	25313218
DrugRepV_5768	Lanatoside C	Cardiovascular agents	Arrhythmia	Dengue virus	Singapore isolates		Plaque assay	Decrease (89 %)	Experimental	25251726
DrugRepV_5769	Digitoxin	Cardiovascular agents	Arrhythmia	Dengue virus	Singapore isolates		Plaque assay	Decrease (94 %)	Approved	25251726
DrugRepV_5770	Digoxin	Cardiovascular agents	Arrhythmia	Dengue virus	Singapore isolates		Plaque assay	Decrease (92 %)	Approved	25251726
DrugRepV_5771	Hycanthone	Antischistosomal	Parasitic infections	Dengue virus	Singapore isolates		Plaque assay	Decrease (90 %)	Experimental	25251726
DrugRepV_5772	Cetrimonium Bromide	Dermatologicals	Sepsis	Dengue virus	Singapore isolates		Plaque assay	Decrease (90 %)	Approved	25251726
DrugRepV_5773	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections \| Helminthiasis	Dengue virus	Singapore isolates		Plaque assay	Decrease (82 %)	Approved	25251726
DrugRepV_5774	Paroxetine Hydrochloride	Nervous System	Major depressive disorder (MDD) \| Panic disorder \| Obsessive-compulsive disorder (OCD) \| Social anxiety disorder (social phobia) \| Generalized anxiety disorder (GAD) \| Post-traumatic stress disorder (PTSD) \| Premenstrual dysphoric disorder (PMDD)	Dengue virus	Singapore isolates		Plaque assay	Decrease (78 %)	NA	25251726
DrugRepV_5775	Allantoin	NA	NA	Dengue virus	Singapore isolates		Plaque assay	Decrease (78 %)	Approved	25251726
DrugRepV_5776	Mephentermine sulphate	Cardiovascular agents	Hypotension	Dengue virus	Singapore isolates		Plaque assay	Decrease (75 %)	Approved	25251726
DrugRepV_5777	Brucine	NA	NA	Dengue virus	Singapore isolates		Plaque assay	Decrease (75 %)	NA	25251726
DrugRepV_5778	Dicloxacillium Sodium	NA	Bacterial infections	Dengue virus	Singapore isolates		Plaque assay	Decrease (72 %)	Approved	25251726
DrugRepV_5779	Clarithromycin	Antiinfectives For Systemic Use	NA	Dengue virus	Singapore isolates		Plaque assay	Decrease (72 %)	NA	25251726
DrugRepV_5780	Acrisorcin	NA	NA	Dengue virus	Singapore isolates		Plaque assay	Decrease (72 %)	NA	25251726
DrugRepV_5781	Loxapine succinate	Nervous System	Schizophrenia	Dengue virus	Singapore isolates		Plaque assay	Decrease (68 %)	Approved	25251726
DrugRepV_5782	Oxantel Pamoate	NA	NA	Dengue virus	Singapore isolates		Plaque assay	Decrease (68 %)	NA	25251726
DrugRepV_5783	Dioxybenzone	Dermatologicals	Sunburn	Dengue virus	Singapore isolates		Plaque assay	Decrease (65 %)	Approved	25251726
DrugRepV_5784	Mexiletine Hydrochloride	Cardiovascular agents	Ventricular tachycardia \| Symptomatic premature ventricular beats	Dengue virus	Singapore isolates		Plaque assay	Decrease (65 %)	NA	25251726
DrugRepV_5785	Chlormadinone Acetate	Genito Urinary System and Sex Hormones	Atrophic vaginitis and estrogen deficiency	Dengue virus	Singapore isolates		Plaque assay	Decrease (65 %)	NA	25251726
DrugRepV_5786	Candesartan cilexetil	Cardiovascular agents	Hypertension	Dengue virus	Singapore isolates		Plaque assay	Decrease (63 %)	Approved	25251726
DrugRepV_5787	Lasalocid Sodium	NA	NA	Dengue virus	Singapore isolates		Plaque assay	Decrease (62 %)	NA	25251726
DrugRepV_5788	Lanatoside C	Cardiovascular agents	Arrhythmia	Dengue virus	Singapore isolates		Plaque assay	Decrease (50 %)	Experimental	25251726
DrugRepV_5789	Lanatoside C	Cardiovascular agents	Arrhythmia	Dengue virus	Singapore isolates		Plaque assay	Decrease (50 %)	Experimental	25251726
DrugRepV_5790	Lanatoside C	Cardiovascular agents	Arrhythmia	Dengue virus	Singapore isolates		Plaque assay	Decrease (50 %)	Experimental	25251726
DrugRepV_5791	Lanatoside C	Cardiovascular agents	Arrhythmia	Dengue virus	Singapore isolates		Plaque assay	Decrease (90 %)	Experimental	25251726
DrugRepV_5796	Lanatoside C	Cardiovascular agents	Arrhythmia	Dengue virus	Singapore isolates		Plaque assay	Decrease (86.4 %)	Experimental	25251726
DrugRepV_5797	Lanatoside C	Cardiovascular agents	Arrhythmia	Dengue virus	Singapore isolates		Plaque assay	Decrease (95.14 %)	Experimental	25251726
DrugRepV_5798	Lanatoside C	Cardiovascular agents	Arrhythmia	Dengue virus	Singapore isolates		Plaque assay	Decrease (73.79 %)	Experimental	25251726
DrugRepV_5841	Anisomycin	Antibacterial	Bacterial infections	Dengue virus	NA		Plaque assay	Decrease (5 Logs reduction)	Experimental	22155902
DrugRepV_5842	Lycorine Hydrochloride	Antiviral, Antimalarial, Anticancer and Antiinflammatory	NA	Dengue virus	NA		Plaque assay	Decrease (2 Logs reduction)	NA	22155902
DrugRepV_5843	Strophanthidin Acetate	NA	NA	Dengue virus	NA		Plaque assay	Decrease (5 Logs reduction)	NA	22155902
DrugRepV_5844	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	NA		Plaque assay	Decrease (5 Logs reduction)	Experimental	22155902
DrugRepV_5845	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	NA		Plaque assay	Decrease (50 %)	Experimental	22155902
DrugRepV_5846	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	NA		Plaque assay	Decrease (50 %)	Experimental	22155902
DrugRepV_5847	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	NA		Plaque assay	Decrease (50 %)	Experimental	22155902
DrugRepV_5848	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	NA		Plaque assay	Decrease (50 %)	Experimental	22155902
DrugRepV_5852	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	NA		Plaque assay	No significant effect	Experimental	22155902
DrugRepV_5853	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	NA		Plaque assay	Decrease (3.8 Logs reduction)	Experimental	22155902
DrugRepV_5854	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	NA		Plaque assay	Decrease (5 Logs reduction)	Experimental	22155902
DrugRepV_5860	N-Desmethylclozapine	Antipsychotic	Schizophrenia \| Schizoaffective disorders	Dengue virus	NA		Plaque assay	Decrease (50 %)	Investigational	27572397
DrugRepV_5861	Fluoxetine	Nervous System	Major depressive disorder \| Bulimia nervosa \| Obsessive-compulsive disorder \| Premenstrual dysphoric disorder \| Panic disorder with or without agoraphobia	Dengue virus	NA		Plaque assay	Decrease (50 %)	Approved, Vet approved	27572397
DrugRepV_5862	Salmeterol	Respiratory System	Asthma \| Chronic obstructive pulmonary disease	Dengue virus	NA		Plaque assay	Decrease (50 %)	Approved	27572397
DrugRepV_5875	N-Desmethylclozapine	Antipsychotic	Schizophrenia \| Schizoaffective disorders	Dengue virus	NA		Plaque assay	Decrease (1.5 Fold)	Investigational	27572397
DrugRepV_5876	Fluoxetine	Nervous System	Major depressive disorder \| Bulimia nervosa \| Obsessive-compulsive disorder \| Premenstrual dysphoric disorder \| Panic disorder with or without agoraphobia	Dengue virus	NA		Plaque assay	Decrease (2 Fold)	Approved, Vet approved	27572397
DrugRepV_5877	Salmeterol	Respiratory System	Asthma \| Chronic obstructive pulmonary disease	Dengue virus	NA		Plaque assay	Decrease (2.5 Fold)	Approved	27572397
DrugRepV_5881	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (78 %)	Approved	24680954
DrugRepV_5882	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (58 %)	Approved	24680954
DrugRepV_5883	Chloroquine ethyl phenyl Mustard	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (> 99 %)	NA	24680954
DrugRepV_5884	Chloroquine Mustard	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (> 99 %)	NA	24680954
DrugRepV_5885	Chloroquine Pamoate	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_5886	Chloroquine Sulfate	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (30 %)	NA	24680954
DrugRepV_5887	Apoquinine	Antiparasitic	Malaria	Dengue virus	NA		Plaque assay	Decrease (38 %)	NA	24680954
DrugRepV_5888	Primaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	No significant effect (0 %)	Approved	24680954
DrugRepV_5889	Quinine Hydrobromide Hydrate	Antiparasitic products, Insectisides and Repellents	Malaria \| Leg cramps	Dengue virus	NA		Plaque assay	Decrease (38 %)	NA	24680954
DrugRepV_5890	Quinacrine Mustard	NA	Malaria \| Giardiasis \| Cutaneous leishmaniasis \| Management of malignant effusions	Dengue virus	NA		Plaque assay	Decrease (> 99 %)	Experimental	24680954
DrugRepV_5891	Amodiaquine derivative (AQD1)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (90 %)	NA	24680954
DrugRepV_5892	Amodiaquine derivative (AQD2)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (70 %)	NA	24680954
DrugRepV_5893	Amodiaquine derivative (AQD3)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (100 %)	NA	24680954
DrugRepV_5894	Amodiaquine derivative (AQD4)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (100 %)	NA	24680954
DrugRepV_5895	Amodiaquine derivative (AQD5)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (20 %)	NA	24680954
DrugRepV_5896	Amodiaquine derivative (AQD6)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (100 %)	NA	24680954
DrugRepV_5897	Amodiaquine derivative (AQD7)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (97 %)	NA	24680954
DrugRepV_5898	Amodiaquine derivative (AQD8)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	No significant effect (0 %)	NA	24680954
DrugRepV_5899	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	Approved	24680954
DrugRepV_5900	Amodiaquine derivative (AQD1)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_5901	Amodiaquine derivative (AQD2)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_5902	Amodiaquine derivative (AQD3)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_5903	Amodiaquine derivative (AQD4)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_5904	Amodiaquine derivative (AQD5)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_5905	Amodiaquine derivative (AQD6)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_5906	Amodiaquine derivative (AQD7)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_5907	Amodiaquine derivative (AQD8)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_5908	Quinacrine Mustard	NA	Malaria \| Giardiasis \| Cutaneous leishmaniasis \| Management of malignant effusions	Dengue virus	NA		Plaque assay	Decrease (50 %)	Experimental	24680954
DrugRepV_5909	Chloroquine Mustard	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_5910	Chloroquine ethyl phenyl Mustard	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_5911	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	Approved	24680954
DrugRepV_5912	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	Approved	24680954
DrugRepV_5913	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	Approved	24680954
DrugRepV_5916	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (98 %)	Approved	24680954
DrugRepV_5917	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (90 %)	Approved	24680954
DrugRepV_5918	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (90 %)	Approved	24680954
DrugRepV_5919	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (100 %)	Approved	24680954
DrugRepV_5920	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (80 %)	Approved	24680954
DrugRepV_5921	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (100 %)	Approved	24680954
DrugRepV_5922	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	No significant effect	Approved	24680954
DrugRepV_5923	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (2 Fold)	Approved	24680954
DrugRepV_5924	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (3 Fold)	Approved	24680954
DrugRepV_5925	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (90 %)	Approved	24680954
DrugRepV_5926	Amodiaquine derivative (AQD8)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (90 %)	NA	24680954
DrugRepV_5927	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (90 %)	Approved	24680954
DrugRepV_5928	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (90 %)	Approved	24680954
DrugRepV_5934	Prochlorperazine Novamin	Nervous System	Nausea \| Vomiting \| Schizophrenia	Dengue virus	New Guinea C		Plaque assay	Decrease (2 Fold)	Approved	25028694
DrugRepV_5935	Prochlorperazine Dimaleate	Nervous System	Nausea \| Vomiting \| Schizophrenia	Dengue virus	New Guinea C		Plaque assay	Decrease (2.5 Fold)	Approved	25028694
DrugRepV_5936	Prochlorperazine Dimaleate	Nervous System	Nausea \| Vomiting \| Schizophrenia	Dengue virus	New Guinea C		Plaque assay	Decrease (9 Fold)	Approved	25028694
DrugRepV_5937	Prochlorperazine Dimaleate	Nervous System	Nausea \| Vomiting \| Schizophrenia	Dengue virus	New Guinea C		Plaque assay	Decrease (2 Fold)	Approved	25028694
DrugRepV_5946	Prochlorperazine Novamin	Nervous System	Nausea \| Vomiting \| Schizophrenia	Dengue virus	New Guinea C		Plaque assay	Decrease	Approved	25028694
DrugRepV_5947	Prochlorperazine Novamin	Nervous System	Nausea \| Vomiting \| Schizophrenia	Dengue virus	New Guinea C		Plaque assay	Decrease	Approved	25028694
DrugRepV_5948	NITD008	Antiviral	NA	Dengue virus	New Guinea C		Plaque assay	Decrease (50 %)	NA	19918064
DrugRepV_5952	NITD008	Antiviral	NA	Dengue virus	New Guinea C		Plaque assay	Decrease (50 %)	NA	19918064
DrugRepV_5964	NITD008	Antiviral	NA	Dengue virus	MY10245		Plaque assay	Decrease (50 %)	NA	19918064
DrugRepV_5966	NITD008	Antiviral	NA	Dengue virus	D2S10		Plaque assay	Decrease (6.4 Fold)	NA	19918064
DrugRepV_5967	NITD008	Antiviral	NA	Dengue virus	TS01		Plaque assay	Decrease (10 Fold)	NA	19918064
DrugRepV_5970	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	New Guinea		Plaque assay	Decrease	Approved	24773578
DrugRepV_5973	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	New Guinea		Plaque assay	Decrease	Approved	25664975
DrugRepV_5976	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	16681		Plaque assay	Decrease (50 %)	Experimental	15994763
DrugRepV_5977	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	16681		Plaque assay	Decrease (50 %)	Experimental	15994763
DrugRepV_5979	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	NA		Plaque assay	Decrease	Experimental	15994763
DrugRepV_5980	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	NA		Plaque assay	Decrease	Experimental	15994763
DrugRepV_5981	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	NA		Plaque assay	Decrease	Experimental	15994763
DrugRepV_5982	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	NA		Plaque assay	Decrease	Experimental	15994763
DrugRepV_5988	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	S221		Plaque assay	Decrease (>50 %)	Phase II	22867971
DrugRepV_5990	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	NA		Plaque assay	No significant difference	Phase II	27509020
DrugRepV_5991	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	New Guinea		Plaque assay	Decrease (>2 Log (pfu/ml))	Approved	17360676
DrugRepV_5992	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	New Guinea		Plaque assay	Decrease (>2 Log (pfu/ml))	Approved	17360676
DrugRepV_5993	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	New Guinea		Plaque assay	Decrease (>2 Log (pfu/ml))	Approved	17360676
DrugRepV_5998	Saracatinib	Anticancer	Cancer	Dengue virus	New Guinea		Plaque assay	Decrease (2 Log (pfu/ml))	Investigational	17360676
DrugRepV_5999	Saracatinib	Anticancer	Cancer	Dengue virus	New Guinea		Plaque assay	Decrease (2 Log (pfu/ml))	Investigational	17360676
DrugRepV_6000	Saracatinib	Anticancer	Cancer	Dengue virus	New Guinea		Plaque assay	Decrease (2 Log (pfu/ml))	Investigational	17360676
DrugRepV_6001	U18666A	NA	NA	Dengue virus	New Guinea		Plaque assay	Decrease (3 Log (pfu/ml))	NA	22146564
DrugRepV_6005	Imipramine	Nervous System	Depression	Dengue virus	16681		Plaque assay	Decrease (100 %)	Approved	28600536
DrugRepV_6006	Chebulagic Acid	NA	Immunosuppressive and hepatoprotective	Dengue virus	16681		Plaque assay	Decrease (50 %)	NA	23924316
DrugRepV_6007	Punicalagin	Plant pigment	NA	Dengue virus	16681		Plaque assay	Decrease (50 %)	NA	23924316
DrugRepV_6008	Chebulagic Acid	NA	Immunosuppressive and hepatoprotective	Dengue virus	16681		Plaque assay	Decrease (100 %)	NA	23924316
DrugRepV_6009	Punicalagin	Plant pigment	NA	Dengue virus	16681		Plaque assay	Decrease (100 %)	NA	23924316
DrugRepV_6012	Cromolyn	Respiratory System	Allergies and Asthma	Dengue virus	Eden2		Plaque assay	Increase	Approved	23638300
DrugRepV_6014	N-nonyl-deoxynojirimycin	NA	NA	Dengue virus	PL046		Plaque assay	Decrease (4 Log)	NA	11907199
DrugRepV_6121	Quinacrine	NA	Malaria \| Giardiasis \| Cutaneous leishmaniasis \| Management of malignant effusions	Dengue virus	NA		Plaque assay	Decrease (50 %)	Investigational	27889529
DrugRepV_6122	Mefloquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	Approved, Investigational	27889529
DrugRepV_6123	GSK369796	NA	NA	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	27889529
DrugRepV_6188	Bromocriptine	Nervous System	Parkinson disease	Dengue virus	02--20		Plaque assay	Decrease (50 %)	Approved	27181378
DrugRepV_6189	Bromocriptine	Nervous System	Parkinson disease	Dengue virus	16681		Plaque assay	Decrease (50 %)	Approved	27181378
DrugRepV_6190	Bromocriptine	Nervous System	Parkinson disease	Dengue virus	00-40		Plaque assay	Decrease (50 %)	Approved	27181378
DrugRepV_6191	Bromocriptine	Nervous System	Parkinson disease	Dengue virus	09--48		Plaque assay	Decrease (50 %)	Approved	27181378
DrugRepV_6225	Heparin	Blood and Blood Forming Organs	Venous thrombosis	Dengue virus	NGC		Plaque assay	Decrease (50 %)	Approved, Investigational	24583230
DrugRepV_6226	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	16681		Plaque assay	Decrease (1.75 * 10⁵ pfu/ml)	Approved	7201778
DrugRepV_6227	6-MPTF	NA	NA	Dengue virus	16681		Plaque assay	Decrease (2.05 * 10⁶ pfu/ml)	NA	7201778
DrugRepV_6251	3-{[(4-chlorophenyl)methyl]sulfanyl}-5-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-4-methyl-4H-1,2,4-triazole	NA	NA	Dengue virus	NGC		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_6252	2-({[5-(5-methyl-3-phenyl-1,2-oxazol-4-yl)-1,2,4-oxadiazol-3-yl]methyl}sulfanyl)pyridin-1-ium-1-olate	NA	NA	Dengue virus	NGC		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_6253	1-(4-chlorophenyl)-2-({5-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-1,3,4-oxadiazol-2-yl}sulfanyl)ethan-1-one	NA	NA	Dengue virus	NGC		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_6254	1-(2-chlorophenyl)-3-{2-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-1,3-thiazol-4-yl}urea	NA	NA	Dengue virus	NGC		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_6255	2-chloro-6-(4-chlorophenoxy)-4-{4-methyl-5-[(1E)-1-(2-phenylhydrazin-1-ylidene)ethyl]-1,3-thiazol-2-yl}pyridine	NA	NA	Dengue virus	NGC		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_6472	Delphinidin Chloride	NA	NA	Dengue virus	NA		Plaque assay	Decrease	NA	28744282
DrugRepV_6473	Epigallocatechin Gallate	Cardiovascular agents	Hypertension and Diabetic Nephropathy	Dengue virus	NA		Plaque assay	Decrease	Investigational	28744282
DrugRepV_6494	Decitabine	Antineoplastic and Immunomodulating Agents	Myelodysplastic syndrome	Human immunodeficiency virus	NA		Plaque assay	Decrease (50 %)	Approved	20610712
DrugRepV_6495	Gemcitabine	Antineoplastic and Immunomodulating Agents	Ovarian cancer \| Non-small cell lung cance \| Adenocarcinoma of the pancreas	Human immunodeficiency virus	NA		Plaque assay	Decrease (50 %)	Approved	20610712
DrugRepV_6496	Decitabine	NA	Myelodysplastic syndromes +Different types of Cancer	Human immunodeficiency virus	NA		Plaque assay	Decrease (73 %)	NA	20610712
DrugRepV_6497	Hydroxyurea	Antineoplastic and Immunomodulating Agents	Melanoma \| Chronic myelocytic leukemia \| Ovary carcinoma \| Sickle-cell anemia	Human immunodeficiency virus	NA		Plaque assay	Decrease (10 %)	Approved	20610712
DrugRepV_6498	Decitabine	NA	NA	Human immunodeficiency virus	NA		Plaque assay	Decrease (75 %)	NA	20610712
DrugRepV_6499	Gemcitabine	Antineoplastic and Immunomodulating Agents	Ovarian cancer \| Non-small cell lung cance \| Adenocarcinoma of the pancreas	Human immunodeficiency virus	NA		Plaque assay	Decrease (100 %)	Approved	20610712
DrugRepV_7005	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Yellow fever virus	YF17D		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_7006	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	West Nile virus	3000.0259		Plaque assay	Decrease (100 pfu/ml)	Approved	12504563
DrugRepV_7016	Manidipine	Cardiovascular agents	Hypertension	Japanese encephalitis virus	AT31		Plaque assay	Decrease (4 Logs)	Approved, Investigational	28814523
DrugRepV_7017	Cilnidipine	Cardiovascular agents	Hypertension	Japanese encephalitis virus	AT31		Plaque assay	Decrease (4 Logs)	Approved	28814523
DrugRepV_7018	Benidipine Hydrochloride	Cardiovascular agents	Hypertension	Japanese encephalitis virus	AT31		Plaque assay	Decrease (4 Logs)	Approved	28814523
DrugRepV_7019	Pimecrolimus	Dermatologicals	Atopic dermatitis	Japanese encephalitis virus	AT31		Plaque assay	Decrease (5 Logs)	Approved, Investigational	28814523
DrugRepV_7020	Nelfinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Japanese encephalitis virus	AT31		Plaque assay	Decrease (3 Logs)	NA	28814523
DrugRepV_7055	Manidipine	Cardiovascular agents	Hypertension	Japanese encephalitis virus	AT31		Plaque assay	No significant effect	Approved, Investigational	28814523
DrugRepV_7056	Fenretinide	Anticancer	Prostate cancer \| Breast cancer \| Macular degeneration	West Nile virus	NA		Plaque assay	Decrease (3 Logs)	Investigational	25313218
DrugRepV_7058	Fenretinide	Anticancer	Prostate cancer \| Breast cancer \| Macular degeneration	Polio virus	NA		Plaque assay	Decrease	Investigational	25313218
DrugRepV_7059	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (98 %)	Approved	24680954
DrugRepV_7060	Primaquine	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (20 %)	Approved	24680954
DrugRepV_7061	Chloroquine ethyl phenyl Mustard	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (> 99 %)	NA	24680954
DrugRepV_7062	Chloroquine Mustard	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (> 99 %)	NA	24680954
DrugRepV_7063	Chloroquine Pamoate	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (10 %)	NA	24680954
DrugRepV_7064	Chloroquine Sulfate	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	No significant effect (0 %)	NA	24680954
DrugRepV_7065	Apoquinine	Antiparasitic	Malaria	West Nile virus	NA		Plaque assay	Decrease (56 %)	NA	24680954
DrugRepV_7066	Primaquine	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	No significant effect (0 %)	Approved	24680954
DrugRepV_7067	Quinine Hydrobromide Hydrate	Antiparasitic products, Insectisides and Repellents	Malaria \| Leg cramps	West Nile virus	NA		Plaque assay	No significant effect (0 %)	NA	24680954
DrugRepV_7068	Quinacrine Mustard	NA	Malaria \| Giardiasis \| Cutaneous leishmaniasis \| Management of malignant effusions	West Nile virus	NA		Plaque assay	Decrease (> 99 %)	Experimental	24680954
DrugRepV_7069	Amodiaquine derivative (AQD1)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (98 %)	NA	24680954
DrugRepV_7070	Amodiaquine derivative (AQD2)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_7071	Amodiaquine derivative (AQD3)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (100 %)	NA	24680954
DrugRepV_7072	Amodiaquine derivative (AQD4)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (100 %)	NA	24680954
DrugRepV_7073	Amodiaquine derivative (AQD5)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (80 %)	NA	24680954
DrugRepV_7074	Amodiaquine derivative (AQD6)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (100 %)	NA	24680954
DrugRepV_7075	Amodiaquine derivative (AQD7)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (100 %)	NA	24680954
DrugRepV_7076	Amodiaquine derivative (AQD8)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (60 %)	NA	24680954
DrugRepV_7077	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (50 %)	Approved	24680954
DrugRepV_7078	Amodiaquine derivative (AQD1)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_7079	Amodiaquine derivative (AQD2)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_7080	Amodiaquine derivative (AQD3)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_7081	Amodiaquine derivative (AQD4)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_7082	Amodiaquine derivative (AQD5)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_7083	Amodiaquine derivative (AQD6)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_7084	Amodiaquine derivative (AQD7)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_7085	Amodiaquine derivative (AQD8)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_7086	Quinacrine Mustard	NA	Malaria \| Giardiasis \| Cutaneous leishmaniasis \| Management of malignant effusions	West Nile virus	NA		Plaque assay	Decrease (50 %)	Experimental	24680954
DrugRepV_7087	Chloroquine Mustard	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_7088	Chloroquine ethyl phenyl Mustard	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_7089	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Polio virus	Sabin		Plaque assay	No significant effect	Approved	26585243
DrugRepV_7090	NITD008	Antiviral	NA	West Nile virus	New York 3356		Plaque assay	Decrease (50 %)	NA	19918064
DrugRepV_7091	NITD008	Antiviral	NA	Yellow fever virus	17D vaccine strain		Plaque assay	Decrease (50 %)	NA	19918064
DrugRepV_7096	Imipramine	Nervous System	Depression	West Nile virus	WT		Plaque assay	Decrease (100 %)	Approved	28600536
DrugRepV_7097	Abamectin	NA	Helmintic infection	Yellow fever virus	17D		Plaque assay	Decrease (5.3 Log)	Terminated	26752081
DrugRepV_7098	Berberine	NA	Parasitic and fungal infection	Yellow fever virus	17D		Plaque assay	No significant effect (No significant effect Log)	Approved	26752081
DrugRepV_7099	Bromocriptine	Nervous System	Parkinson disease	Yellow fever virus	17D		Plaque assay	No significant effect (No significant effect Log)	Approved	26752081
DrugRepV_7100	Cerivastatin	Cardiovascular agents	Rhabdomyolysis	Yellow fever virus	17D		Plaque assay	No significant effect (No significant effect Log)	Approved	26752081
DrugRepV_7101	Fenretinide	Anticancer	Prostate cancer \| Breast cancer \| Macular degeneration	Yellow fever virus	17D		Plaque assay	Decrease (3 Log)	Investigational	26752081
DrugRepV_7102	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis \| Onchocerciasis	Yellow fever virus	17D		Plaque assay	Decrease (5.3 Log)	Approved, Investigational, Vet approved	26752081
DrugRepV_7107	Arbidol	NA	Viral infection	Polio virus	NA		Plaque assay	Decrease (50 %)	Phase IV	22028179
DrugRepV_7109	N-nonyl-deoxynojirimycin	NA	NA	Japanese encephalitis virus	RP-9		Plaque assay	Decrease (3 Logs)	NA	11907199
DrugRepV_7251	3-{[(4-chlorophenyl)methyl]sulfanyl}-5-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-4-methyl-4H-1,2,4-triazole	NA	NA	West Nile virus	Kunjin		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7252	2-({[5-(5-methyl-3-phenyl-1,2-oxazol-4-yl)-1,2,4-oxadiazol-3-yl]methyl}sulfanyl)pyridin-1-ium-1-olate	NA	NA	West Nile virus	Kunjin		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7253	1-(4-chlorophenyl)-2-({5-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-1,3,4-oxadiazol-2-yl}sulfanyl)ethan-1-one	NA	NA	West Nile virus	Kunjin		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7254	1-(2-chlorophenyl)-3-{2-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-1,3-thiazol-4-yl}urea	NA	NA	West Nile virus	Kunjin		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7255	2-chloro-6-(4-chlorophenoxy)-4-{4-methyl-5-[(1E)-1-(2-phenylhydrazin-1-ylidene)ethyl]-1,3-thiazol-2-yl}pyridine	NA	NA	West Nile virus	Kunjin		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7256	3-{[(4-chlorophenyl)methyl]sulfanyl}-5-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-4-methyl-4H-1,2,4-triazole	NA	NA	Yellow fever virus	17D		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7257	2-({[5-(5-methyl-3-phenyl-1,2-oxazol-4-yl)-1,2,4-oxadiazol-3-yl]methyl}sulfanyl)pyridin-1-ium-1-olate	NA	NA	Yellow fever virus	17D		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7258	1-(4-chlorophenyl)-2-({5-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-1,3,4-oxadiazol-2-yl}sulfanyl)ethan-1-one	NA	NA	Yellow fever virus	17D		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7259	1-(2-chlorophenyl)-3-{2-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-1,3-thiazol-4-yl}urea	NA	NA	Yellow fever virus	17D		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7260	2-chloro-6-(4-chlorophenoxy)-4-{4-methyl-5-[(1E)-1-(2-phenylhydrazin-1-ylidene)ethyl]-1,3-thiazol-2-yl}pyridine	NA	NA	Yellow fever virus	17D		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7315	CW-33A	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	30413749
DrugRepV_7316	CW-33	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	30413749
DrugRepV_7326	N-(6-methanesulfonyl-1,3-benzothiazol-2-yl)-4-[(4-nitro-1H-pyrazol-1-yl)methyl]benzamide	NA	NA	Japanese encephalitis virus	P3		Plaque assay	Decrease (2 log pfu/ml)	NA	27679979
DrugRepV_7327	N-[6-({[(thiophen-2-yl)formamido]methanethioyl}amino)-1,3-benzothiazol-2-yl]butanamide	NA	NA	Japanese encephalitis virus	P3		Plaque assay	Decrease (2 log pfu/ml)	NA	27679979
DrugRepV_7332	CW-33	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (5 times pfu/ml)	NA	27563890
DrugRepV_7333	CW-33	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (3 times pfu/ml)	NA	27563890
DrugRepV_7334	CW-33	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	27563890
DrugRepV_7335	FGIN-1-27	NA	NA	Japanese encephalitis virus	P3		Plaque assay	Decrease (2 log %)	NA	24348901
DrugRepV_7336	Cilnidipine	Cardiovascular agents	Hypertension	Japanese encephalitis virus	P3		Plaque assay	Decrease (2 log %)	Investigational	24348901
DrugRepV_7337	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections \| Helminthiasis	Japanese encephalitis virus	P3		Plaque assay	Decrease (2 log %)	Approved	24348901
DrugRepV_7348	Indigo	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	22911608
DrugRepV_7349	Indirubin	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	Investigational	22911608
DrugRepV_7353	S-nitroso-N-acetylpenicillamine	NA	NA	Japanese encephalitis virus	NT109		Plaque assay	Decrease (3 log pfu/ml)	NA	9188590
DrugRepV_7372	Luteolin	NA	NA	Japanese encephalitis virus	SX09S01		Plaque assay	Decrease (50 %)	NA	27126774
DrugRepV_7373	Luteolin	NA	NA	Japanese encephalitis virus	SX09S01		Plaque assay	Decrease (2 log Log PFU/ml)	NA	27126774
DrugRepV_7375	Chrysophanol	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	24395532
DrugRepV_7376	Aloe-emodin	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	24395532
DrugRepV_7377	Aloe-emodin	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	18701259
DrugRepV_7378	Aloe-emodin	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	18701259
DrugRepV_7379	Shikonin	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	18701259
DrugRepV_7380	Shikonin	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	18701259
DrugRepV_7381	Arecoline	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	Experimental	18701259
DrugRepV_7382	Arecoline	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	Experimental	18701259
DrugRepV_7383	Hesperetin	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	Experimental	18701259
DrugRepV_7384	Dehydroepiandrosterone	NA	Schizophrenia	Japanese encephalitis virus	NT113		Plaque assay	Decrease	Approved	16099910
DrugRepV_7389	Delphinidin Chloride	NA	NA	West Nile virus	NY-99		Plaque assay	Decrease (O.6 Log)	NA	28744282
DrugRepV_7390	Cyanidin Chloride	NA	NA	West Nile virus	NY-99		Plaque assay	No significant effect (No significant effect Log)	NA	28744282
DrugRepV_7391	Catechin	Antioxidant	NA	West Nile virus	NY-99		Plaque assay	No significant effect (No significant effect Log)	NA	28744282
DrugRepV_7392	Epicatechin	NA	Pre-diabetes	West Nile virus	NY-99		Plaque assay	No significant effect (No significant effect Log)	Investigational	28744282
DrugRepV_7393	Epigallocatechin	NA	NA	West Nile virus	NY-99		Plaque assay	Decrease (0.5 Log)	Experimental	28744282
DrugRepV_7394	Epigallocatechin Gallate	Cardiovascular agents	Hypertension and Diabetic Nephropathy	West Nile virus	NY-99		Plaque assay	Decrease (1.1 Log)	Investigational	28744282
DrugRepV_7397	Nordihydroguaiaretic Acid	NA	Actinic keratoses	West Nile virus	NY-99		Plaque assay	Decrease (50 %)	Approved, Investigational	28507114
DrugRepV_7398	Nordihydroguaiaretic Acid	NA	Actinic keratoses	West Nile virus	NY-99		Plaque assay	Decrease (50 %)	Approved, Investigational	28507114
DrugRepV_7399	Resveratrol	Anticancer	Herpes labialis infections (cold sores)	West Nile virus	NY-99		Plaque assay	Decrease (0.6 Log)	Approved, Experimental, Investigational	28507114
DrugRepV_7400	PF-429242	NA	NA	West Nile virus	NY-99		Plaque assay	Decrease (0.4 Log)	NA	28507114
DrugRepV_7401	Fatostatin	NA	NA	West Nile virus	NY-99		Plaque assay	Decrease (0.7 Log)	NA	28507114
DrugRepV_7402	Zileuton	NA	Asthma	West Nile virus	NY-99		Plaque assay	No significant change (No significant change Log)	Approved / Withdrawn	28507114
DrugRepV_7403	BCX4430	NA	Ebola virus	West Nile virus	Eg101		Plaque assay	Decrease (50 %)	Investigational	28336346
DrugRepV_7404	BCX4430 Hydrochloride	NA	Ebola virus	West Nile virus	Eg101		Plaque assay	Decrease (50 %)	Investigational	28336346
DrugRepV_7517	Aloe-emodin	NA	NA	Enterovirus	EV71		Plaque assay	Decrease (50 %)	NA	18701259
DrugRepV_7518	Aloe-emodin	NA	NA	Enterovirus	EV71		Plaque assay	Decrease (50 %)	NA	18701259
DrugRepV_7519	Rifampicin	Antiinfectives For Systemic Use	Tuberculosis and Tuberculosis-related mycobacterial infections	Vaccinia virus	NA		Plaque assay	Decrease (Complete inhibition Plaque size)	Approved	4321450
DrugRepV_7905	RK-33	NA	NA	Dengue virus	New Guinea C		Plaque assay	Decrease (50 %)	NA	31936642
DrugRepV_7906	RK-33	NA	NA	Zika virus	Asian/Cook Islands/2014	NA	Plaque assay	Decrease (50 %)	NA	31936642
DrugRepV_7907	RK-33	NA	NA	West Nile virus	Kunjin		Plaque assay	Decrease (50 %)	NA	31936642
DrugRepV_7986	Silymarin	Alimentary tract and metabolism	NA	Enterovirus	41		Plaque assay	Decrease (50 %)	NA	32293397
DrugRepV_7987	Baicalein	Plant extract	Influenza	Enterovirus	41		Plaque assay	Decrease (50 %)	Phase II	32293397
DrugRepV_8299	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	Paraiba_01	NA	Plaque assay	Decrease (50 %)	NA	32326119
DrugRepV_8300	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MR-766	NA	Plaque assay	Decrease (50 %)	NA	32326119
DrugRepV_8301	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	West Nile virus	Eg101		Plaque assay	Decrease (50 %)	NA	32326119
DrugRepV_8302	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	West Nile virus	13-104		Plaque assay	Decrease (50 %)	NA	32326119
DrugRepV_8303	Tipranavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	Paraiba_01	NA	Plaque assay	Decrease (50 %)	Approved, Investigational	32326119
DrugRepV_8304	Tipranavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MR-766	NA	Plaque assay	Decrease (50 %)	Approved, Investigational	32326119
DrugRepV_8305	Tipranavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	West Nile virus	Eg101		Plaque assay	Decrease (50 %)	Approved, Investigational	32326119
DrugRepV_8306	Tipranavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	West Nile virus	13-104		Plaque assay	Decrease (50 %)	Approved, Investigational	32326119
DrugRepV_8307	Dasabuvir	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	Paraiba_01	NA	Plaque assay	Decrease (50 %)	Approved	32326119
DrugRepV_8308	Dasabuvir	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	MR-766	NA	Plaque assay	Decrease (50 %)	Approved	32326119
DrugRepV_8309	Dasabuvir	Antiinfectives For Systemic Use	Hepatitis C virus	West Nile virus	Eg101		Plaque assay	Decrease (50 %)	Approved	32326119
DrugRepV_8310	Dasabuvir	Antiinfectives For Systemic Use	Hepatitis C virus	West Nile virus	13-104		Plaque assay	Decrease (50 %)	Approved	32326119
DrugRepV_8457	Berberine	NA	Parasitic and fungal infection	Zika virus	NA	NA	Plaque assay	Decrease (50 %)	Approved	30641880
DrugRepV_8458	Emodin	NA	Polycystic Kidney	Zika virus	NA	NA	Plaque assay	Decrease (50 %)	Investigational	30641880